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Bacterial Outer Membrane Vesicles (OMVs) are naturally produced by all Gram-negative 
bacteria and play a key role in their biology and pathogenesis. Over the last few years, OMVs 
have become an increasingly attractive vaccine platform for three main reasons. First, they 
contain several Microbe-Associated-Molecular Patterns (MAMPs), crucial for stimulating 
innate immunity and promoting adaptive immune responses. Second, they can be easily 
purified from the culture supernatant, thus making their production process inexpensive and 
scalable. Third, OMVs can be engineered with foreign antigens. However, the OMV platform 
requires some optimization for a full-blown exploitation. First, OMVs carry a number of 
endogenous proteins that would be useful to eliminate to avoid possible interference of 
immune responses toward the vaccine antigens. Second, OMVs carry abundant quantities of 
lipopolysaccharide (LPS). LPS is a potent stimulator of the immune system, therefore is 
essential for OMV adjuvaticity, but such adjuvanticity has to be modulated to avoid 
reactogenicity. In this study, we have addressed the two issues by creating a strain releasing 
OMVs with a minimal amount of endogenous proteins and containing a detoxified LPS. In 
particular, we first developed a CRISPR/Cas9-based genome editing tool which allows the 
inactivation of any “dispensable” gene in two working days. The efficacy and robustness of 
this tool was validated on 78 “dispensable genes”. Using our CRISPR/Cas9 protocol, an OMV 
proteome-minimized E. coli strain, named E. coli BL21(DE3)Δ58, deprived of 58 OMV 
associated proteins was created. We demonstrated that E. coli BL21(DE3)Δ58 had growth 
kinetics similar to the progenitor strain and featured a remarkable increase in OMV 
production. Two additional genes involved in the LPS biosynthetic pathway (msbB and pagP) 
were subsequently inactivated creating E. coli BL21(DE3)Δ60 which released OMVs with a 
substantially reduced reactogenicity. The exploitation of the two strains in vaccine 
applications was finally validated. We successfully engineered E. coli BL21(DE3)Δ58 and E. coli 
BL21(DE3)Δ60 with several different antigens, demonstrating that such antigens 
compartmentalized with high efficiency in the OMVs. We also demonstrated that the 
engineered OMVs from E. coli BL21(DE3)Δ58 and E. coli BL21(DE3)Δ60-derived OMVs elicited 






5.1 A brief history of vaccination  
The evidence, described more than 2.500 years ago by the Greek historian Thucydides (429 
BC), that people who recovered from smallpox plaques rarely re-experienced the disease, 
constitutes the ground of modern Vaccinology. Indeed, such evidence made ancient 
physicians and sorcerers believe that the pustules appearing on the skins of smallpox patients 
not only represented the signs of the disease but also contained the “magic recipe” which 
protected patients from re-infection. Therefore, over the centuries, pioneer vaccinologists 
devised different strategies to manipulate pustule extracts to be subsequently administered 
to healthy people and protect them during epidemics. The first written documents on 
successful vaccination date back to 1000 A. D. in China, where variola scabs were exposed to 
air or heat and insufflated into the nose of people as immunization strategy against smallpox1. 
The practice of inoculation, from Latin inoculare which means “to graft”, was performed not 
only in China but most likely in other countries, including Africa and India2. 
Vaccination was introduced in Europe by Lady Mary Wortley Montagu, wife of the English 
ambassador Edward Wortley Montagu. The family lived in Turkey in 1716 where she 
witnessed the inoculation practice and once returned to England she inoculated her daughter 
in front of the scrutiny of the Royal Society’s Physicians2. The practice started to gain 
popularity until few cases of death occurred after inoculation. Clearly, the pre-treatment of 
the vaccine was very rudimental and sometimes insufficient to fully inactivate the “unknown”, 
with the consequence that the inoculated people could become infected and source of 
disease transmission. As a consequence, the practice was abandoned for some time.  
The procedure was subsequently re-adopted in 1751-1753 during a severe smallpox epidemic 
and was routinely used until the introduction of the safer vaccination practice developed by 
Edward Jenner1,3. It was common knowledge that during smallpox epidemics farmers had a 
much lower risk to become infected. Since cattle develop a disease (cowpox) whose 
manifestation resembles smallpox for the appearance of cutaneous scabs, Edward Jenner had 
the intuition that if people were intentionally administrated with biological material collected 
from the animal lesions they could become resistant to smallpox disease. In 1796, he 
inoculated a young boy with cowpox and subsequently intentionally challenged the boy with 
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extracts of pustules from human patients. As Jenner predicted, the boy did not develop the 
disease3,4. In 1798, Jenner published his work, representing the first human vaccine trial ever 
reported, and vaccination against smallpox became a common practice and culminated in 
global eradication of smallpox in 1979. 
In the nineteenth century, bacteria were finally discovered and microbial pathogens were 
associated with the insurgency of infectious diseases. Louis Pasteur was the first to develop 
live attenuated cholera vaccine and anthrax vaccine, after the observation that the pathogens 
could be made less virulent by exposure to oxygen, high temperature and chemicals5.  
The practice of pathogen attenuation was further developed by Albert Calmette and Camille 
Guérin who used culturing in artificial media to attenuate Mycobacterium bovis, a bovine 
tuberculosis bacteria, to protect against human tuberculosis. Moreover, Max Theiler used 
several passages in mice and chicken embryos to attenuate Yellow fever virus6 and his 
attenuated strain represents one of the most effective vaccines ever developed and is still 
routinely administered in countries where yellow fever is endemic. 
 
In the middle of the 20th century, the cell culture was utilized to attenuate the virulence of 
viruses through several passages in culture2. In this period, many vaccines based on 
attenuated viruses, including those for poliomyelitis (polio), measles, rubella, mumps and 
varicella, were developed 7,8,9,10. The passages in cell cultures are usually carried out at a sub-
physiological temperature and lead to strain adaptation to the new culture conditions and the 
loss lose or modification of genes involved in virulence and transmission in the human host. 
One of the best examples is the oral polio vaccine (OPV). The attenuate poliovirus elicits 
protection without causing disease since it is unable to replicate efficiently in the nervous 
system11.  
Live/attenuated OPV has been a triumph in the history of human health having almost 
eradicated poliomyelitis from the world. However, the OPV vaccine was not completely safe: 
in one out of 3 million vaccines the attenuated virus can revert to the wild type form and 
become virulent and infective11. For this reason, it has been replaced with fully inactivated 
vaccines and nowadays live/attenuated pathogens are rarely considered as a valid option for 
the development of new vaccines.  
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As technology advanced, it became possible to purify specific components of the pathogen of 
interest and use such components as vaccines. Typical examples are toxins (i.e. diphtheria, 
tetanus and cholera vaccines), capsular polysaccharides (i.e. Hib, pneumococcal and 
meningococcal vaccines) and proteins (i.e. pertussis vaccine).  
In the 21st century, there are still a number of pathogens for which vaccines have not been 
developed yet and such pathogens represent a serious threat for human health particularly 
in consideration of the dramatic increase of antibiotic resistance. High throughput 
technologies and improved knowledge of microbial pathogenesis and immunology now offer 
new opportunities to identify protective antigens and to discover novel adjuvants, which can 
better orchestrate the effector functions of the immune system. 
 
5.2 How vaccines work 
To be effective vaccines should induce the same natural immunity that our organism develops 
in response to infection. Therefore, a rational vaccine design should stem from the knowledge 
of how our immune system develops natural immunity. 
At the site of entry, microbes are recognized by the cells of the innate immunity, which 
provide immediate defense against the invasion and trigger the cascade of events leading to 
the adaptive immune responses (Figure 1).  
The innate immune cells include phagocytic cells, such as macrophages, that not only 
phagocytose and kill the invaders but also release cytokines in response to the recognition, 
through pattern-recognition receptors (PRRs), of conserved components of the pathogens 
(microbial-associated molecular patterns (MAMPs)12). Cytokine release is responsible for the 
induction of an inflammatory response, which recruits additional phagocytic cells and initiates 
the adaptive immune response. The key cellular components involved in the activation of 
adaptive immunity are the dendritic cells (DCs). Like macrophages, DCs recognize pathogens 
via PRRs and release cytokines. Furthermore, they phagocytose pathogens and extracellular 
antigens by endocytosis, digest pathogen-derived proteins into small fragments (epitopes) 
and present such fragments on their surface in the context of the Major Histocompatibility 
Complexes (MHC) class I and II. Then, DCs migrate to the draining lymph nodes through the 
lymphatic system and present the MHC I/MHC II-bound epitopes to naïve T cells. Naive T cells 
thus become effector CD4+ and CD8+ T cells. Effector CD4+ T cells stimulate the production 
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of pathogen-specific antibodies and migrate to the site of infection where they exert their 
effector functions by potentiating the phagocytic activity of phagocytic cells. Effector CD8+ T 
cells also reach the infection site, but they function by directly killing cells infected by 
intracellular pathogens such as viruses.  
 
 
Figure 1: Stimulation of the innate and adaptive immune system by adjuvant. Figure taken from 
www.ozbiosciences.com. (1) recruitment of APC at the injection site. (2) enhancement of antigen uptake. (3) 
enhancement of Th2 response. (4) enhancement of humoral immune response. (5) improvement of 
NALP3/inflammasome in mac. 
 
Antibodies, produced by B cells after stimulation by effector CD4+ T cells, exert anti-microbial 
activity through different mechanisms. First, they can bind to secreted toxins and neutralize 
their toxic action. Second, antibodies can bind the pathogen and prevents its interaction with 
host cells and tissues. Third, antibodies bound to the pathogen are recognized by receptors 
on phagocytic cells, thus facilitating phagocytosis. Forth, antibodies can activate the 
complement system, which leads to the direct lysis of bacteria or to pathogen phagocytosis. 
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Finally, antibodies can bind the surface of infected cells which are killed by NK cells, a process 
known as antibody-dependent cell-mediated cytotoxicity (ADCC)13. 
As said above, a key step for the activation of adaptive immunity is the recognition of MAMPs 
by PRRs, the best characterized of which are the Toll-like receptors (TLRs) and NOD-like 
receptors (NLRs). TRLs have a central role in sensing different MAMPs, including 
unmethylated double-stranded DNA (CpG), single- and double-stranded RNA, lipoproteins, 
lipopolysaccharide (LPS), peptidoglycan, and flagella14,15. PRR activation stimulates the release 
of cytokine and chemokines16,17. It is important to underlay that PRRs dictate the profile of 
cytokines released by immune cells and consequently the type of adaptive immunity that is 
necessary to eliminate the specific pathogen. For instance, extracellular bacteria stimulate the 
release of IL17 and IL23 which promote recruitment and killing capacity of phagocytic cells 
while viruses stimulate the release of IFN which elicits cytotoxic CD8+ T cells.  
According to these mechanisms, it appears that effective vaccines have to be tailored to 
induce the proper immune response required to eliminate the specific pathogens they are 
made for. Moreover, it becomes clear why vaccines based on attenuated viruses, such as 
yellow fever, measles and polio OPV vaccines, are generally very effective: being alive and 
non-virulent copies of their progenitors they elicit exactly what is needed in terms of quality, 
quantity, and location of immune responses. Furthermore, the above also explains why 
subunit-based vaccines, in addition to contain proper antigens, should include specific 
components, known as adjuvants, which by stimulating the correct PRRs activate the type of 
immune response necessary to prevent infection. 
 
5.3 Approved adjuvants and new challenges 
The importance of adjuvants was recognized very early in vaccination. As introduced earlier, 
the first written document of successful vaccination come from the China of 1000 A.D. They 
had the intuition to formulate a mixture of variola scabs from mildly affected patients, stored 
for at least 1 month, with Uvularia grandiflora in a 4:1 ratio before intranasal inoculation. 
Therefore, Uvularia grandiflora can be considered as the first attempt at using an adjuvant. 
In modern vaccinology, the first molecules to be used as adjuvants were phosphate or 
hydroxide salts of aluminium (known as alum). Alum was originally discovered as a good  
antigen delivery system and in 1926 Glenny and Pope showed that alum-absorbed diphtheria 
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toxoid was a more potent vaccine compared to the antigen alone18. Although the mode of 
action is still not exactly clear, it is now understood that alum increases antigen uptake by 
APCs at the site of injection. In addition, alum stimulates NALP3 Inflammasome complex, 
which is required for the processing of several pro-inflammatory cytokines that ultimately 
activate inflammatory DCs capable of priming T cells19. Alum was first approved for tetanus 
and diphtheria toxoids vaccines and it is currently formulated in one-third of the vaccines 
present on the market20. Interestingly, no other adjuvant for human use was introduced for 
several decades (Figure 2), until 1997 when MF59 was licensed as a part of vaccines against 
pandemic influenza strains such as H5N1 or H7N921. MF59 is an oil-in-water emulsion 
prepared with squalene and biodegradable/biocompatible oil22. Like alum, MF59 is a delivery 
system. Furthermore, it appears that MF59 has the ability to upregulate the production of 
cytokines and chemokines which attract APCs to the site of injection increasing antigen uptake 
and subsequent transport to draining lymph node23. AS03 is another squalene-based 
emulsion with the addition of Alpha-tocopherol (vitamin E) licensed in 2009. Despite their 
success, all these adjuvants are not potent inducers of cytotoxic T cell responses and therefore 
they are not very effective against intracellular pathogens and cancer.  
Table 1: Approved and in clinical trials adjuvants (from Luis A. Brito, Derek T. O'Hagan, 2014) 
 
The discovery that changed the game of adjuvant formulation and raised the potential of 
developing novel adjuvants was the understanding of innate immune receptors such as TLRs 
and nucleotide-binding oligomerization domain-like receptors (NLR). Agonists of hTLR4 have 
become important adjuvants and are being tested for cancer treatments. One such agonist is 
monophosphoryl lipid A (MPL), purified from Salmonella Minnesota LPS24. MLP was combined 
with Alum to formulate AS04, an adjuvant used for licensed human vaccine preventing human 
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papillomavirus (HPV)25. The combination of MPL/alum adjuvant enhances both effector and 
memory B-cell immunity26. The stimulation of hTLR4 results in the production of IL-12 and 
increased expression of MHC class II and costimulatory molecules. Many others PRR agonists 
have been studied, such oligonucleotides containing CpG motifs (CpG ODN). They act by 
binding the intracellular TLR9, expressed in the vesicular compartment of immune cells. CpG 
ODN have been extensively studied in clinical trials as powerful inducers of Th1, including 
antibody and antigen-specific T cell production27. Other examples are imiquimod (R837), 
resiquimod (R848) and 3M-052, synthetic TLR7/8 agonists reported to exert potent adjuvant 
activities by inducing robust antigen-specific humoral and Th1 type cellular immunity. TLR 
agonists have been so far proved to be effective adjuvants with some molecules licensed for 
human use and many others in clinical trials for use in both vaccines against pathogens and 
cancer vaccines.  
 
Figure 2: Time line of approved adjuvants for human use. 
 
A new pathway that has been investigated recently as a candidate vaccine adjuvant is STING 
(STimulator of INterferon Genes). STING is an endoplasmic reticulum transmembrane protein 
belonging to the family of nucleic acid sensors28. It is activated by cytosolic dsDNA from 
pathogens or self-DNA from stressed or damaged cells in cyclic GMP-AMP synthase (cGAS) 
dependent manner. Cytosolic DNA is detected by cGAS, it functions as a second messanger 
that binds and activates STING. STING activation triggers TBK-1/IRF-3 signaling cascades 
inducing the expression IFN-β as well IKK/NFKB-dependent upregulation of inflammatory 
cytokines and chemokines29. In preclinical models the use of c-GMP have shown good results, 
c-di-GMP injected intratumorally demonstrated to induce caspase 3-dependent apoptosis of 
tumor cells and release of tumor-associated antigens promoting DCs activation and CD8+ T-
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cell responses against those antigens27. At present, one STING agonist, 5,6-
dimethylxanthenone-4-acetic acid (DMXAA)30, has reached the clinics. 
 
5.4 Outer Membrane Vesicles 
More than 50 years ago, researchers observed that Gram-negative bacteria secrete OMVs31. 
However, only the last 15 to 20 years have brought a greater understanding of the regulation 
and function of vesiculation. OMVs are closed spheroid particles of heterogeneous size, 50-
300 nm in diameter, generated through a “budding out” of the bacterial outer membrane 
and, consistently, the majority of their components are represented by LPS, 
glycerophospholipids, outer membrane proteins and periplasmic proteins31,32 (Figure 3).  
 
 
Figure 3: Outer Membrane Vesicles biogenesis and composition (from Jan et al., 2017). 
 
OMVs represent a distinct secretory pathway with a multitude of functions, including inter 
and intra species cell-to-cell cross-talk, biofilm formation, genetic transformation, defense 
against host immune responses, and toxin and virulence factor delivery to host cells32,33. 
OMVs interaction to host cells can occur by endocytosis after binding to host cell receptors or 
lipid rafts. Alternatively, OMVs have been reported to fuse to host cell membrane, leading to 
the direct release of their content into the cytoplasm of the host cells34. 
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OMVs purified from several pathogens, including Neisseria, Salmonella, Pseudomonas, Vibrio 
cholerae Burkholderia, and E. coli35,36,37, induce potent protective immune responses against 
the pathogens they derive from, and highly effective anti-Neisseria OMV-based vaccines are 
already available for human use38. Such remarkable protection is attributed to three key 
features of OMVs. First, they are readily phagocytosed by professional antigen-presenting 
cells, which get activated and present OMV-derived peptides on MHC class II and MHC class 
I. Second, they carry the proper immunogenic antigens, which, in extracellular pathogens, 
usually reside on the surface and therefore are naturally incorporated in OMVs. Indeed, OMV 
immunization induces potent antibody responses against the major membrane-associated 
antigens. However, OMV immunogenicity is not restricted to antibody responses. For 
instance, mice immunized with Salmonella OMVs develop robust Salmonella-specific B and T 
cell responses, and OMVs stimulate IFN- production by a large proportion of CD4+ T cells 
from mice previously infected with Salmonella, indicating that OMVs are an abundant source 
of antigens recognized by Salmonella-specific CD4+ T cells35. Third, and most importantly, 
OMVs carry several MAMPs which, by binding to PPRs, play a key role in stimulating innate 
immunity and promoting adaptive immune responses. OMV-associated MAMPs include LPS 
which, in concert with MD-2 and CD14, binds TLR-4, lipoproteins, which interact with TLR-2, 
and peptidoglycan, which binds to intracellular NOD139. Engagement of this group of PPRs 
results in the expression of cytokines through the activation of NF-KB transcription factor. 
Interestingly, LPS, lipoproteins and peptidoglycan can work synergistically, thus potentiating 
the built-in adjuvanticity of OMVs40.  
Two additional keys features make OMVs particularly attractive for vaccine applications. First, 
several studies have demonstrated that OMV protein content can be manipulated by genetic 
engineering. Kesty and Kuehn demonstrated that Yersinia enterocolitica outer membrane 
protein Ail assembled on OMVs surface when expressed in E. coli, and that the GFP 
fluorescence protein fused to the “twin arginine translocation (TAT)” signal sequence was 
incorporated in the OMV lumen41. Furthermore, a number of heterologous proteins have 
been successfully exported to the surface of OMVs when fused to the -barrel forming 
autotransporter AIDA and the hemolysin ClyA, two proteins that naturally compartmentalized 
in E. coli OMVs42. In our laboratory, we have devised effective strategies to incorporate 
heterologous antigens in the lumen of OMVs43 and in their membrane (Irene et. al, manuscript 
submitted) and we have shown that foreign polypeptides can be delivered to the OMV surface 
by fusing them to lipoproteins44. Second, using hyper-vesiculating mutant strains, OMVs can 
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be easily purified from the culture supernatant and their purification process can be promptly 
scaled-up from the laboratory to industrial levels44,43,45,46. Once the supernatant is separated 
from the biomass, the purification of the vesicles can be carried out using tangential flow 
filtration with production yield higher than 100 mg of vesicles (protein content) per liter of 
culture47 under GMP conditions.   
In conclusion, OMVs represent a promising vaccine platform due to their built-in adjuvanticity, 
the possibility of manipulation and simplicity of the production process.  
For a full-blown development of OMVs as vaccine platform, three potential limitations have 
to be overcome.  
First, as said above, OMVs have remarkable adjuvanticity properties thanks to the presence 
of several MAMPs, which, stimulate different innate immunity receptors. In particular, LPS is 
present in OMVs at a concentration of approximately 0.5 mg per mg of total OMV proteins48 
and by binding to TLR4, LPS substantially contributes to adjuvanticity. However, LPS 
abundance is also responsible for OMV reactogenicity, which has to be reduced for human 
use. A number of mutations in the LPS biosynthetic pathway have been described that reduce 
the TLR4 agonistic activity of LPS by removing acyl chains to the hexa-acylated lipid A moiety. 
They include the inactivation of the acyl-transferase genes msbB and pagP which results in 
the synthesis of a LPS carrying a penta-acylated lipid A49,50. In our laboratory, we have also 
exploited the inactivation of genes involved in the LPS biosynthetic pathway to modulate 
adjuvanticity/reactogenicity of OMVs (manuscript submitted).  
Second, as already pointed out, the possibility of being manipulated makes OMVs particularly 
attractive for vaccine applications and several strategies have been devised to decorate OMVs 
with heterologous antigens. The ideal system should (i) be highly flexible, allowing OMV 
compartmentalization of most heterologous antigens, and (ii) result in the accumulation of 
sufficiently large quantities of heterologous antigens, allowing the elicitation of proper anti-
antigen immune responses. The development of novel OMV engineering strategies is an 
active field of translational research and our laboratory is particularly active on this line of 
activity.  
Third, proteomic data indicate that OMVs incorporate approximately 100-150 major 
endogenous proteins present in the outer membrane and periplasmic compartments of the 
OMV producing strains51,52,53. All these proteins are potentially immunogenic and therefore 
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could “dilute” or even partially suppress the immune responses against the desired antigens. 
Therefore, the availability of mutant strains which release OMVs with a minimal amount of 
endogenous proteins would be highly desirable. This later aspect has been the major interest 
of my PhD experimental work which has been focused on the systematic inactivation of the 
genes encoding a large set of proteins present in the OMVs released by E. coli BL21(DE3) strain.  
 
5.5 Construction of KO mutants in Escherichia coli 
Being E. coli one of the most extensively studied organisms on earth for both scientific and 
translational purposes, several procedures have been described for gene knock-out and 
knock-in. 
Currently, there are three main approaches for manipulation of chromosomal DNA in E. coli, 
all utilizing phage recombinase-mediated homologous recombination (recombineering), 
using either the Rac prophage system54,55 or the three bacteriophage  Red proteins Exo, Beta, 
and Gam56,57.  
The first approach envisages the creation of knockout mutants by fusing at the 5’ and 3’ ends 
of an antibiotic resistance marker gene (or other selection markers) PCR products preceding 
and following the target gene, respectively. Mutant colonies are isolated in the appropriate 
selective medium after transformation with linear or circular constructs. The selection marker 
is subsequently eliminated by counter-selection, leaving a “scarless” chromosomal 
mutation58.  
In a second approach, Court and co-workers demonstrated that chromosomal gene mutations 
can be achieved without the need of selection markers and using synthetic single stranded 
DNAs (ss-DNAs) or double stranded DNAs (ds-DNAs), which anneal to their complementary 
chromosomal regions and mediate gene modification59.  
The third approach, proposed for the first time by Jiang and co-workers60, makes use of the 
CRISPR/Cas9 technology. Briefly, the Cas9 nuclease and the  Red machinery are genetically 
introduced in the strain to be modified and subsequently the strain is co-transformed with a 
plasmid (pCRISPR) encoding the guide RNA, which promotes the site-specific DNA cleavage by 
the Cas9, and donor DNA (PCR-derived or chemically synthesized) partially homologous to the 
cleaved extremities. This allows the  Red-mediated repair of the cleavage site with the 
concomitant introduction of the desired mutation.  
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While effective, the first two approaches are not ideal for high-throughput applications since 
they are laborious and time-consuming (in the case of the first approach) 58 and feature 
mutagenesis efficiencies often below 1% (in the case of the second approach)59. On the 
contrary, the third approach was shown to lead to efficiencies as high as 50-80%61,62,63. 
However, one aspect of the CRISPR/Cas9 technology that still remained to be thoroughly 
addressed was the “robustness” of the strategy defined as the success rate of mutated loci 
with respect to the number of mutations attempted. Knowing the robustness of the specific 
CRISPR/Cas9-based protocol in use is particularly relevant in high-throughput applications, 
where the repetition of mutagenesis experiments and/or the analysis of large numbers of 




6 Aim of the thesis 
One of the main tasks of our Synthetic and Structural Vaccinology Laboratory at the University 
of Trento, is to exploit the potentiality of OMVs as a vaccine-platform. As already pointed out, 
OMVs have an intrinsic adjuvanticity, can be engineered to express heterologous antigens and 
are easy to produce. However, the presence of E. coli endogenous proteins might affect and 
dilute the immune response against the heterologous antigens engineered in OMVs. To 
mitigate this effect, we decided to reduce the repertoire of homologous proteins present in 
the OMV compartment by systematically knocking out the corresponding genes from the 
OMV-producing strains.  
The aims of my thesis can be summarized as follows: 
1. Identification and selection the OMV endogenous proteins to be deleted 
2. Development of a highly efficient and robust genome editing protocol based on 
CRISPR/Cas9 technology to delete dispensable OMV proteins 
3. Creation of E. coli strains releasing proteome–minimized OMVs, using the gene editing 
platform developed in point 2, and characterization of their growth kinetics and OMV 
production 
4. Analysis of the expression of heterologous antigens in the OMVs released by the 
genetically modified strains  
5. Analysis of antigen-specific antibody and T cell responses induced by proteome-minimized 
OMVs  
This activity has so far led to the publication of one paper (Zerbini et al., 2017) of which I am 
the second author. A second paper, which I will be the first author of, is under submission. 
I also wish to point out that in addition to my main research project I have been involved in 
other activities related to the exploitation of OMVs as vaccines. Such activities have been 
documented in three scientific publications (L. Fantappie’ et al., 2017; A. Grandi et al. 2017; 






As pointed out in the “Aim of the Thesis” the main objectives of my experimental work was 
1) to reduce the repertoire of homologous proteins present in the OMV compartment thus 
generating “proteome-minimized OMVs”, and 2) to test the proteome-minimized OMVs as a 
vaccine platform.   
The reach these objectives, the experimental work has been articulated in the following 
activities: 
- Identification and selection of the OMV endogenous proteins  
- Development of a highly efficient and robust genome editing protocol  
- Creation of E. coli strains releasing proteome–minimized OMVs 
- Analysis of the expression of heterologous antigens in proteome-minimized OMVs 
- Analysis of antigen-specific antibody and T cell responses induced by proteome-
minimized OMVs 
 
7.1 Identification of E. coli OMV proteome  
The composition of OMV proteins was determined in two ways.  
First, purified E. coli BL21ΔompA–derived OMVs were separated by 2D gel electrophoresis 
(2DE) and protein spots were picked and characterized by MALDI-TOF-TOF Mass 
Spectrometry. A total of 114 unique sequences were identified corresponding to 69 unique E. 
coli proteins44.  
Second, bioinformatics analysis of total E. coli predicted proteins was carried out using 
different algorithms (Proteome Analyst, SOSUI-GramN and PSORTb version 3.0.2) to predict 
periplasmic and outer membrane proteins. These proteins are those which are expected to 
be found in the OMV compartment. The in-silico analysis predicted 504 E. coli proteins 
localized in the outer membrane (OM) or in the periplasm (P) of E. coli. Interestingly and as 
expected, all 69 proteins experimentally identified by 2D-gel mass spectrometry were 
included in the in silico predicted proteins, with the exception for tuf1, elongation factor Tu 
1, and pdxB, erythronate-4-phosphate dehydrogenase, encoded proteins and YghJ, a 
hypothetical inner-membrane protein. 
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Once the OMV proteome was defined, we next selected among the 504 proteins those whose 
deletion should be attempted to create a mutant strain releasing proteome-minimized OMVs.  
The selection was carried out in two steps. First, the “essential proteins” included in the 504 
protein list were eliminated by inspecting the Keio collection, a database in which all viable 
and non-viable single-gene knockout E. coli K-12 mutations are reported. Second, we ranked 
the dispensable proteins on the basis of their predicted or experimentally verified level of 
expression, with the idea to focus our attention on the most abundant ones. This combined 
approach led us to define the list of 90 proteins reported in Table 2. These proteins have been 
the focus of our genome editing activity.  
 
Table 2: List of 90 selected OMV-related proteins. For each protein a UniProt accession number has been assigned 






Annotation (according to UniProt) 
P19926 agp  Glucose-1-phosphatase 
P45565 ais Lipopolysaccharide core heptose(II)-phosphate phosphatase 
P30859 artI  Putative ABC transporter arginine-binding protein 2 
P30860 artJ ABC transporter arginine-binding protein 1 
P77774 bamB Outer membrane protein assembly factor BamB 
P0A903 bamC Outer membrane protein assembly factor BamC 
P0A937 bamE Outer membrane protein assembly factor BamE 
P37650 bcsC Cellulose synthase operon protein C 
P33363 bglX  Periplasmic beta-glucosidase 
P0AB40 bhsA Multiple stress resistance protein BhsA 
P77330 borD Prophage lipoprotein Bor homolog 
P17315 cirA Colicin I receptor 
P45955 cpoB Cell division coordinator CpoB 
P0C0V0 degP Periplasmic serine endoprotease DegP 
P39099 degQ Periplasmic pH-dependent serine endoprotease DegQ 
P0AEG6 dsbC Thiol:disulfide interchange protein DsbC 
P0ADB7 ecnB Entericidin B 
P23827 eco  Ecotin 
P0AB24 efeO Iron uptake system component EfeO 
P0C960 emtA Endo-type membrane-bound lytic murein transglycosylase A 
P10384 fadL  Long-chain fatty acid transport protein 
P13036 fecA  Fe(3+) dicitrate transport protein FecA 
P05825 fepA Ferrienterobactin receptor 
P06971 fhuA  Ferrichrome outer membrane transporter/phage receptor 
P45523 fkpA FKBP-type peptidyl-prolyl cis-trans isomerase FkpA 
24 
 
P26648 ftsP Cell division protein FtsP 
P0AEQ3 glnH  Glutamine-binding periplasmic protein 
P09394 glpQ  Glycerophosphodiester phosphodiesterase, periplasmic 
P37902 gltI Glutamate/aspartate import solute-binding protein 
P0AEU0 hisJ  Histidine-binding periplasmic protein 
Q03961 kpsD Polysialic acid transport protein KpsD 
P02943 lamB  Maltoporin 
P25894 loiP Metalloprotease LoiP 
P45464 lpoA Penicillin-binding protein activator LpoA 
P0AB38 lpoB Penicillin-binding protein activator LpoB 
P69776 lpp Major outer membrane prolipoprotein Lpp 
P0AEX9 malE  Maltose/maltodextrin-binding periplasmic protein 
P03841 malM  Maltose operon periplasmic protein 
P40120 mdoD Glucans biosynthesis protein D 
P33136 mdoG Glucans biosynthesis protein G 
P0A908 mipA MltA-interacting protein 
P76506 mlaA Intermembrane phospholipid transport system lipoprotein MlaA 
P0ADV7 mlaC Intermembrane phospholipid transport system binding protein MlaC 
P0A935 mltA  Membrane-bound lytic murein transglycosylase A 
P0ADA3 nlpD  Murein hydrolase activator NlpD 
P40710 nlpE Lipoprotein NlpE 
P21420 nmpC  Putative outer membrane porin protein NmpC 
P0A910 ompA Outer membrane protein A 
P77747 ompN Outer membrane protein N 
P0A917 ompX  Outer membrane protein X 
P23843 oppA Periplasmic oligopeptide-binding protein 
P0ADB1 osmE Osmotically-inducible putative lipoprotein OsmE 
P0A912 pal Peptidoglycan-associated lipoprotein 
P02932 phoE Outer membrane pore protein E 
P0A921 pldA Phospholipase A1 
P0AFK9 potD Spermidine/putrescine-binding periplasmic protein 
P0AFL3 ppiA Peptidyl-prolyl cis-trans isomerase A 
P23865 prc Tail-specific protease 
P0AFM2 proX  Glycine betaine/proline betaine-binding periplasmic protein 
P05458 ptrA Protease 3 
P69411 rcsF Outer membrane lipoprotein RcsF 
P10100 rlpA Endolytic peptidoglycan transglycosylase RlpA 
P0AEU7 skp Chaperone protein Skp 
P37194 slp  Outer membrane protein slp 
P0A905 slyB Outer membrane lipoprotein SlyB 
P0ABZ6 surA Chaperone SurA 
P13482 treA Periplasmic trehalase 
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P0A927 tsx Nucleoside-specific channel-forming protein Tsx 
P07024 ushA Protein UshA 
P0ADA5 yajG Uncharacterized lipoprotein YajG 
P77717 ybaY Uncharacterized lipoprotein YbaY 
P0AAX8 ybis Probable L,D-transpeptidase YbiS 
P0A8X2 yceI Protein YceI 
P64451 ydcL  Uncharacterized lipoprotein YdcL 
P77318 ydeN Uncharacterized sulfatase YdeN 
P76177 ydgH Protein YdgH 
P76537 yfeY Uncharacterized protein YfeY 
P0AD44 yfhG Uncharacterized protein YfhG 
P65292 ygdI  Uncharacterized lipoprotein YgdI 
P65294 ygdR Uncharacterized lipoprotein YgdR 
P0ADS6 yggE Uncharacterized protein YggE 
P0CK95 yghJ Putative lipoprotein AcfD homolog 
P0ADU5 ygiW  Protein YgiW 
P64614 yhcN Uncharacterized protein YhcN 
P37648 yhjJ  Protein YhjJ 
P37665 yiaD  Probable lipoprotein YiaD 
P0ADN6 yifL Uncharacterized lipoprotein YifL 
P0AF70 yjeI Uncharacterized protein YjeI 
P76115 yncD  Probable TonB-dependent receptor YncD 
P76116 yncE Uncharacterized protein YncE 
P64596 yraP Uncharacterized protein YraP 
 
7.2 Genome editing protocol base on CRISPR/Cas9 
To carry out the systematic cumulative inactivation of the 90 selected proteins, it was first 
necessary to build-up a robust and reliable high-throughput (HTP) genome-editing protocol. 
The development of such HTP protocol, which is based on the CRISPR/Cas9 technology and is 
described below, has been the first task of my experimental activity.  
General description of the CRISPR/Cas9 protocol for genome editing 
The CRISPR/Cas9 protocol developed in the Synthetic and Structural Vaccinology Laboratory 
is composed of three elements: pCasRed plasmid, pCRISPR-SacB-gDNA plasmid, and the 
synthetic, mutation-inducing oligonucleotide (donor DNA) (Figure 4). The pCasRed plasmid 
and pCRISPR-SacB-gDNA derive respectively from pCas9 (ADDGENE # 42876) and pCRISPR 
plasmid (ADDGENE # 42875)64, respectively. The pCasRed carries, under the control of a 
constitutive promotor, (i) the Cas9 nuclease, (ii) the tracRNA, and (iii) the Chloramphenicol 
resistance cassette (ClmR). Furthermore and importantly, the plasmid expresses, under the 
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pBAD arabinose inducible promoter65, the λ Red (Exo, Beta, Gam) machinery, necessary to 
promote homologous recombination. The pCRISPR-SacB-gDNA plasmid carries the synthetic 
DNA fragment (gDNA) expressing the guide RNA and the SacB gene fused to the Kanamycin 
resistance gene (KmR). SacB gene encodes the Bacillus subtilis levansucrase enzyme. The 
enzyme catalyzes the hydrolysis of sucrose, generating products that are toxic for E. coli66.  
 
 
Figure 4: Overview of CRISPR/Cas9 genome editing strategy in Escherichia coli (from Zerbini et al., 2017). The strain to 
be mutagenized [E. coli BL21(DE3)∆ompA] is first transformed with the pCasRed plasmid expressing the λ Red (Exo, 
Beta, Gam) machinery, the Cas9 endonuclease, and tracrRNA. Subsequently, the strain is co-transformed with pCRISPR-
SacB-gDNA, and a synthetic, mutation-inducing oligonucleotide [donor DNA (dDNA)]. The pCRISPR-SacB-gDNA plasmid 
encodes the gRNA that specifies the site of cleavage and the endonuclease Cas9 recognizes the gRNA together with the 
tracrRNA, which anneals to gRNA forming a three-component complex. After the base pairing of gRNA to the target 
site, the Cas9 mediates the chromosomal DNA double strand break (upper panel). The double strand break is repaired 
by λ Red-mediated homologous recombination taking place between the extremities of the cleaved chromosomal DNA 
and the donor DNA (lower panel).  
 
According to our protocol, the E. coli strain that has to be modified at a specific target locus is 
transformed with pCasRed plasmid. Subsequently, the strain is co-transformed with pCRISPR-
SacB-gDNA and the donor DNA (dDNA). The Cas9 nuclease, guided by the gRNA, drives the 
cleavage of the genomic DNA at the target site, thus producing a double strand break (DSB). 
The DSB is repaired by λ Red-mediated homologous recombination taking place between the 
extremities of the cleaved chromosomal DNA and the donor DNA (Figure 4). This protocol was 
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fine-tuned by investigating how it was affected by 1) selection of gDNA, 2) length and 
concentration of dDNA, 3) extension of gene deletion. 
Selection of guide DNA 
gDNAs are usually selected among those 30 nucleotide sequences followed by an NGG (PAM) 
trinucleotide which in the target gene do not share homologies with other regions in the 
chromosome (to avoid off-target cleavage). Routine bioinformatics tools (BLAST) are generally 
used to identify such sequences. However, what has not been fully investigated is the 
robustness of bioinformatics in gDNA selection.  
To establish the effectiveness of gDNAs, we created sets of pCRISPR-gDNA plasmids and we 
compared the transformation efficiencies of the recombinant plasmids with the efficiency of 
the “empty” pCRISPR vector. In particular, we selected three target genes, ompF, lpp and fecA, 
and we designed four sets of different gDNAs, two of them targeting different sites at the 5’ 
and 3’ regions of ompF gene, respectively, and the other two sets targeting lpp and fecA at 
different positions. Colonies were selected on LB plates supplemented with Cm and Km. While 
the “empty” pCRISPR vector routinely gave a transformation efficiency of 0.5 – 2x106 CFUs/g 
of plasmid DNA, most of pCRISPR-gDNA plasmids had transformation efficiencies in the range 
of 0.5 – 2x103 CFUs/g of plasmid DNA (Figure 5), indicating that the gDNA properly mediated 
DSBs. However, two out of the 20 pCRISPR-gDNA plasmids (pCRISPR-ompF 5’_C and pCRISPR-
lpp_C) gave a transformation efficiency close to the one observed with the empty vector, 
suggesting these two gDNA inefficiently mediated Cas9 cleavage. 
From these experiments, we concluded that in silico selection allows the identification of 
gDNAs, which in most cases drive the Cas9-mediated cleavage with high efficiency. However, 
approximately 10% of selected gDNAs did not cause bacterial killing. “Good and bad” gDNAs 
can easily be discriminated by colony counting after transformation with the by colony 
counting after transformation with the pCRISPR plasmids carrying the selected gDNAs. 
Therefore, before modifying any target gene we routinely run the colony testing and if 
transformation efficiencies higher than 103 CFUs/g of plasmid DNA are obtained we change 




Figure 5: Selection of gDNAs for mutation of ompF, lpp and fecA genes (from Zerbini et al., 2017). The grey bars are a 
schematic drawing of the genes lpp, fecA and ompF, and the black lines labelled with letters indicate the positions where 
the gRNAs transcribed from their corresponding gDNAs hybridize within each gene. The tables report the 
transformation efficiencies (CFU/μg) of each pCRISPR-gDNA in BL21(DE3)∆ompA. 
 
Selection of the optimal conditions for gene knockout 
To investigate the optimal condition for gene inactivation using the CRISPR/Cas9 protocol, 
four parameters were analyzed: length and concentration of the mutagenic dDNA, extent of 
gene deletion and type of donor DNA. The parameters were tested targeting four loci: the 5′ 
end of the ompF gene the 3′ end of the ompF gene, and the fecA and lpp genes. As a donor 
DNA, single stranded DNA (ssDNA) oligos annealing to the lagging strand (Lg-ss-dDNAs) or to 
the leading strand (Ld-ss-dDNA) and double strand DNA were used. The donor DNA were 
120nt or 70nt long and were designed with homology arms of equal length upstream and 
downstream of the desired deletion. In addition, different concentrations, 1 and 10 ug, of 
donor DNA were used to test the gene knockout efficiency. All parameters were tested in 
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three different experiments and at least 20 colonies were analyzed to determine the mutation 
efficiency (Table 3). 
 
Table 3: Influence of type of donor DNA (dDNA) (Lg-ss-dDNAs, Ld-ss-dDNAs, ds-dDNA) length of dDNA, concentration 



















70 ∆30 1 86% (19/22) 
70 ∆30 10 95% (40/42)  
ompF 5'G-70-∆100 70 ∆100  10 5% (2/36) 
ompF 5'G-70-∆500 70 ∆500  10 0% (0/30)  
ompF 5'G-120-∆30 
120 ∆30 1  64% (40/62) 
120 ∆30 10 93% (76/82) 
ompF 5'G-120-∆100 120 ∆100  10 64% (20/31) 
ompF 5'G-120-∆500 120 ∆500  10 47% (14/30) 
ompF 5'G-120-∆1089 120 ∆1180  10 0% (0/20)  
Ld-ss  ompF 5'G-70-∆30 R 70 ∆30 10 20% (4/20) 
ompF 5'G-120-∆30 R 120 ∆30 10 100% (10/10) 
ompF 5'G-120-∆1089 R 120 ∆1180  10 0% (0/>100) 
ds ompF 5'G-120-∆30 ds 120 ∆30 10 77% (20/26) 
ompF 5'G-120-∆500 ds 120 ∆500  10 50% (15/30) 
ompF 5'G-120-∆1089 ds 120 ∆1180  10 26% (6/23)  
ompF 3'- 
pCRISPR-ompF_3'I 
Lg-ss  ompF 3'I-70-∆30 70 ∆30 10 79% (19/24) 
ompF 3'I-120-∆30 120 ∆30 10 83%(25/30) 
fecA- 
pCRISPR-fecA_B 
Lg-ss  fecA B-70-∆30 70 ∆30 10 43% (13/30) 
fecA B-120-∆30 120 ∆30 10 77% (23/30) 
fecA B-120-∆100 120 ∆100  10 20% (6/30) 
fecA B-120-∆500 120 ∆500  10 13% (4/30)  
fecA B-120-∆2325  120 ∆2325  10 0% (0/30) 
ds fecA B-120-∆2325 ds 120 ∆2325  10 14% (5/35)  
lpp- 
pCRISPR-lpp_B 
Lg-ss  lpp B-70-∆30 R 70 ∆30 10 20% (4/20) 
lpp B-120-∆30 R 120 ∆30 10 55% (11/20) 
lpp B-120-∆237 R 120 ∆237  10 0%(0/16) 
Ld-ss  lpp B-70-∆30 70 ∆30 10 90% (27/30) 
lpp B-120-∆30 120 ∆30 10 73% (19/26) 
lpp B-120-∆237  120 ∆237  10 0% (0/30) 
ds lpp B-120-∆30 ds 120 ∆30 10 82% (19/23) 




As far as ss-dDNA is concerned, both 70 and 120 base donor oligonucleotides (10 ug/ml) gave 
mutagenesis efficiency greater that 40% when 30 bp deletions were produced. However, for 
deletions longer than 30 bp, the 70 base ss-dDNA performed very poorly resulting in a 
mutation efficiency lower than 5%. The mutagenic efficiency was improved by extending the 
length of the oligonucleotide from 70 to 120 base ss-dDNA, allowing deletions around up to 
500 nt with sufficiently good efficiencies. However, ss-dDNA performed very poorly for 
deletions bigger than 500 nt. Finally, the use of 120 bp long ds-dDNA, not only performed at 
least as well as ss-dDNA for short and medium deletions, but also allowed the full gene 
deletion of all the three target genes (lpp: 237 nt, ompF: 1180 nt and fecA: 2325 nt).  
In summary, to achieve short deletions, 70 and 120 bp ss-dDNA oligonucleotides targeting 
either the lagging or leading strand perform similarly well with mutagenic efficiency between 
50 and 100%. However, to achieve high frequency of long deletions 120 bp ds-dDNA is 
required.   
Validation of 30 bp gene deletions for mutant library production 
To validate the protocol described above, a list of 78 “dispensable” genes were selected. The 
design and selection of the 78 pCRISPR-SacB-gDNAs plasmids were performed according to 
the rules described above. The gDNAs were designed to target the genes next to their 5′ ends 
of the open reading frame to avoid the expression of truncated proteins. Then, the gDNAs 
were cloned into pCRISPR-SacB-gDNAs plasmid and the efficacy of the gRNA to guide the Cas9 
cleavage was tested by colony-counting. Since seven out of 78 gDNAs did not promote the 
cleavage of the target site, new gDNAs were designed and re-tested for these genes. After 
selecting optimal gDNAs, 70 nt long ss-dDNA oligonucleotides were designed for all target 
genes to delete around 30 bp and to introduce a premature stop codon in each gene. Of these 
78 dDNAs, 46 targeted the leading strand and 32 the lagging strand. For each gene, its 
corresponding pCRISPR-SacB and its ss-dDNA was used to co-transform E. coli 
BL21(DE3)ΔompA(pCasRed) strain, giving a transformation efficiency between 2 and 5x102 
CFUs/ug of plasmid DNA. Ten colonies were tested by PCR for each transformation to identify 
the percentage of those colonies carrying the 30 bp deletion on the target gene. Overall, 48 
out of 78 genes selected were successfully mutated (Figure 6A). In particular, 20 out of 46 
genes were successfully inactivated using the Lg-ss-dDNA, while, 28 out of 32 genes had the 




Figure 6: Validation of 30 bp deletions on 78 genes (from Zerbini et al., 2017). E. coli BL21(DE3)∆ompA(pCasRed) or E. 
coli BL21(DE3)(pCasRed) were transformed with different mixtures of pCRISPR-SacB-gDNAs and 70-base dDNAs (either 
ssDNA or dsDNA) to mediate 30 bp deletion at one of the 78 selected gene loci (y axis). X axis indicates the percentage 
of mutants identified out of the total number of colonies analyzed. Bar height indicates the mutation frequency, while 
the presence of flat colored squares above gene names in each graph indicates that no mutants were identified out of 
ten colonies analyzed. Absence of bars or flat colored squares above gene names indicate that the gene mutation was 
not attempted for those specific genes in the experiment indicated in each bar graph. Red bars/squares indicate 
mutation experiments using Ld-ss-dDNAs; Blue bars/squares indicate mutation experiments using Lg-ss-dDNAs; Green 
bars/squares indicate mutation experiments using ds-dDNAs; bars with green downward diagonals indicate mutation 
experiments with ds-dDNAs in BL21(DE3)(pCasRed). (A) Bar graph representing mutation success rate using 46 Ld-ss-
dDNAs (red bars/squares) and 32 Lg-ss-dDNAs (blue bars/squares). (B) Gene mutations that failed using the Ld-ss-DNAs 
(26 genes out of 46) and the Lg-ss-DNAs (4 genes out of 32) were re-attempted using ss-dDNAs targeting the opposite 
strands. (C) The bar graph represents the mutation success rate in BL21(DE3)∆ompA(pCasRed) (green bars) and in 
BL21(DE3)(pCasRed) (green downward diagonal bars) using ds-dDNAs 
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To verify if the type of donor ss-DNA (leading vs lagging ss-DNA) has a role on the mutation 
frequency for those 30 genes that were not mutated, or at least not with a frequency equal 
or higher than 10% (1 colony out of 10), the mutagenic experiment was performed using the 
ss-dDNA targeting the opposite strand (Figure 6B). Regarding the 26 genes that failed to be 
mutated using the Ld-ss-dDNA, 14 were inactivated using Lg-ss-dDNA, while only 1 mutant 
was rescued using the Ld-ss-dDNA out of the 4 not obtained using the Lg-ss-dDNA.  
Summarizing, 42 mutagenesis were obtained out of 58 targeted genes using Lg-ss-dDNA, 
corresponding to a success rate of 72%. On the other hand, targeting the leading strand with 
ss-dDNA the success rate was 43% corresponding to 22 inactivated genes out of 51 mutagenic 
experiments. Moreover, the average mutagenic frequency obtained with Ld-ss-dDNA was 
10% compared with the 30% obtained using Lg-ss-dDNA.  
Finally, we attempted the inactivation of the genes that failed to be mutated with ss-dDNA 
using as a donor 70 bp ds-dDNAs. As shown in Figure 6C, all genes were successfully mutated. 
The conclusion of the extensive mutagenesis experiments carried out in BL21(DE3) strain is 
that our CRISPR/Cas9 gene editing protocol designed to delete 30-100 bp can reach a close to 
100% efficiency and robustness when 70-120 bp ds-dDNA are used. 
Creation of multi-gene mutants by a stepwise approach 
Considering our goal to generate a multi-gene KO strain releasing proteome-minimized OMVs, 
we needed a genome editing tool not only efficient and robust, but that allowed to rapidly 
generate mutants in a stepwise modality. Therefore, we tested the performance of our 
genome editing protocol by testing the time needed to create the two-genes (fecA and lpp) 
mutant.  
First, BL21(DE3)ΔompA(pCasRed) strain was co-transformed with pCRISPR-SacB-fecA_B 
plasmid and the ds-dDNA 120 base oligo fecA_B-120-∆30. The day after 10 colonies were 
screened and 7 carried the expected mutation (70% mutagenesis efficiency) (Figure 7). One 
mutant clone was cultured overnight in LB media supplemented with Cm and 5% of sucrose. 
Under these conditions, the pCRISPR-SacB-fecA_B was lost during overnight growth by virtue 
of the fact that the plasmid carries the SacB gene. This gene encodes an enzyme which 
catalyzes the production of high molecular weight fructose polymers, which are toxic for E. 
coli, and therefore, in order to survive, bacterial cells must lose pCRISPR-SacB-fecA_B. 
Competent cells were made from the overnight culture of (BL21(DE3) ΔompA/ΔfecA) and co-
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transformed with pCRISPR-SacB-lpp_B plasmid and with ds-dDNA 120 base lpp_B-120-∆240 
oligo. Colonies screening revealed a 60% efficiency of lpp inactivation (Figure 7).  
In conclusion, our pCRISPR/Cas9 genome editing protocol allows to generate a gene mutation 
every two days and in one week 2 to 3 genes can be inactivated from the same strain using 
the stepwise protocol described above.  
 
Figure 7: Representation of the stepwise approach used to isolate strains carrying multiple mutations (from Zerbini 
et al., 2017). Day 1: E. coli BL21(DE3)∆ompA(pCasRed) was co-transformed with 1 μg/ml of pCRISPR-SacB-fecA_B and 
10 μg/ml of donor fecA-120-∆30nt and transformant colonies were selected on LB agar plates supplemented with Cm 
(25 μg/ml) and Km (50 μg/ml). Day 2: Ten colonies were randomly selected and screened by PCR using primers designed 
to generate DNA fragments from mutated colonies of 200 bp. PCR products were analyzed on 2% agarose gels. One 
mutant clone was subsequently inoculated into 5 ml of LB supplemented with 5% sucrose and 25 μg/ml Cm. Day 3: The 
overnight culture was used to prepare competent cells, which were subsequently co-transformed with 1 μg/ml of 
pCRISPR-SacB-lpp_B and 10 μg of double strand donor DNA lpp-120-∆237. Day 4: Ten colonies were randomly selected 
and screened by PCR using primers designed to generate DNA fragments from mutated colonies of 400 bp. PCR products 




Simultaneous gene deletions 
Another approach that we tested has been the simultaneous inactivation of two genes. To 
this aim, we constructed pCRISPR plasmids encoding two gDNAs targeting two different loci 
of E. coli genome. Mimicking the same organization of the CRISPR arrays in bacteria, the two 
gDNAs were intercalated by the short repeated regions in the configuration “Repeat-gDNA1-
Repeat-gDNA2-Repeat”. The pCRISPR-gDNA1-gDNA2 was used to transform the recipient 
strain with two ds-dDNAs, each designed to repair the target sites cleaved by the Cas9. The 
strategy was first tested to delete two stretches of 30 bp each at the 5’ and 3’ ends of the 
ompF gene. BL21(DE3)ΔompA(pCasRed) was transformed with pCRISPR-ompF_5′G-ompF_3′I 
mixed with the two ds-dDNA ompF_5′G-120-∆30 and ompF_3′I-120-∆30. When colonies were 
analyzed by PCR screening, 12 out of 20 carried the deletion at both sites while only one 




Figure 8: CRISPR/Cas9-based protocol for simultaneous two-gene deletions (from Zerbini et al., 2017). E. coli 
BL21(DE3)∆ompA(pCasRed) was co-transformed with either 100 ng pCRISPR-ompF_5′G-ompF_3′I plasmid and the two 
dDNAs ompF_5′G-120-∆30 and ompF_3′I-120-∆30 (10 μg each) (A) or with 100 ng pCRISPR-lpp_B-fecA_B and lpp_B-
120-∆30 and fecA_B-120-∆30 dDNAs (10 μg each). (B) Transformant colonies were selected on LB agar plates 
supplemented with 25 μg/ml Cm and 50 μg/ml Km. Colony PCR was carried out using two different couple of primers 
to screen each genomic locus (indicated at the bottom of each gel) on a randomly selected number of colonies and the 





Table 4: Efficiency of simultaneous two-loci mutagenesis (ompF 5’/ompF 3’ regions and fecA/lpp genes) using pCRISPR 
plasmids carrying repeat-gDNA1-repeat-gDNA2-repeat cassette (from Zerbini et al., 2017).  
 
 
7.3 Construction of an E. coli strain releasing OMVs deprived of 58 endogenous 
proteins 
With the data reported above, we have been able to demonstrate that our genome editing 
protocol is remarkably efficient and robust and allows to accumulate mutations at a pace of 
one mutation every two working days. Therefore, with this platform technology available we 
decided to initiate the construction of an E. coli strain which releases vesicles with a minimal 
number of endogenous proteins.  
As illustrated in Section 4.2, mass spectrometry and bioinformatics analyses had led us to 
select 90 OMV protein-encoding genes as potential targets for genome editing. 
For each of the 90 genes encoding the selected OMV proteins, gDNA were synthesized, cloned 
into a pCRISPR-SacB-gDNA and tested by colony counting to test their efficiency in guiding 
Cas9 chromosomal cutting. Subsequently, the cumulative inactivation of each gene was 
attempted following the random order reported in Figure 9. Once a gene was inactivated, 
before moving to the next deletion the mutant strain was characterized for its growth rate 
and OMVs production (Figure 9A). Our plan was in fact to eliminate those mutations that 
would have negatively affected growth or the OMV production.  
Growth kinetics analysis was performed in flask. Each strain was inoculated in 50 mL LB-Miller 
and incubated at 30°C under vigorous shaking. The bacterial growth was followed over a 
period of 6 hours. At the end of the 6 hours culture, supernatant was separated by 
centrifugation, OMVs were then collected by ultracentrifugation (32,000 rpm for 2 h at 4°C) 
and the pellet was re-suspended in 100 μL PBS. The volumetric OMVs yield, expressed as total 
milligram protein per liter of bacterial culture, was calculated for each of the mutant E. coli 





Figure 9: Creation and characterization of E. coli BL21(DE3)Δ58 strain. (A) The chronological order of the 91 genes 
knock out. Underlined in grey are the genes that were not possible to delete, in green the genes that were inactivated. 
Each bar represent the volumetric OMVs yield (mg/l) of each strain performed in flask in a 50 ml volume at 30 °C for 6h, 
supernatant was separated by centrifugation, OMVs were then collected by ultracentrifugation (32,000 rpm for 2 hr at 
4°C) and the pellets were re-suspended in 100 μl PBS. (B) Classification of the 91 selected proteins for their 
compartmentalization. 45 proteins were identified as periplasmatic proteins (blue), 32 proteins were categorized as 
outer membrane lipoproteins (yellow) and 14 proteins as outer membrane β barrel proteins/porins (red). (C) 
Distribution of each protein category among the entire set of selected genes; those who we successfully deleted (filled 
pies) and the genes we could not delete (dashed pies). (D) The 91 selected proteins were classified in 8 function 
categories represented with the black bars, those who were successfully deleted are represented with dashed bars, 
while those we could not delete are represented with blue bars.  
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At the end, 57 OMV-associated genes out of 90 were successfully mutated, obtaining the E. 
coli strain named “BL21(DE3)Δ58”, since counting the ompA mutation, it features the 
inactivation of 58 genes encoding OMV localized proteins (Figure 9A). This strain produced 
significantly more OMVs than its progenitor E. coli BL21(DE3)ΔompA. 
Figure 9B groups the 90 proteins according to their cellular compartmentalization. As 
illustrated in the Figure 9B, 45 proteins belong to the periplasmic space (PP), 31 proteins are 
outer membrane lipoprotein (OM-LP) and 15 proteins are integral membrane protein (OM-
BP/P). Interestingly, almost 90% of the 15 OM-BP/P proteins were successfully eliminated in 
BL21(DE3)Δ58 while the compatibility of the simultaneous elimination of the selected PP and 
OM-LP proteins dropped to about 55-60% (Figure 9C). Not surprisingly, most of the proteins 
whose function was associated to transport and metabolism could be eliminated while the 
simultaneous inactivation of proteins involved in envelope structure, metabolism and 
biosynthesis was less permissible (Figure 9D).  
The correctness of the deletions created in each of the 58 genes of E. coli BL21(DE3)Δ58 was 
verified in two ways.  
First, specific primer pairs were designed upstream and downstream from the deleted regions 
to amplify approx. 200 bp DNA fragments from the chromosomal DNA of E. coli BL21(DE3)Δ58. 
The same primers on E. coli BL21(DE3)ΔompA DNA as a template should generate fragments 
30 bp longer and such difference could be appreciated on a 2% agarose gel (Figure 10). 
Second, the genome of E. coli BL21(DE3)Δ58 was fully sequenced and the sequence analysis 
confirmed the deletions in each of the 58 genes. 
 
Figure 10: Agarose gel showing PCR amplified fragments of all 58 genes mutated in E. coli BL21(DE3)Δ58. The images 
show the difference in size (30 nucleotides) comparing the PCR products obtained using DNA template either from E. 
coli BL21(DE3)ΔompA (left lane of the designated gene) or the E. coli BL21(DE3)Δ58 strain created in this study (right 
lane of the designated gene). 
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We finally verified whether the gene deletions resulted in the disappearance of the 
corresponding proteins from OMVs. To this aim, OMVs from E. coli BL21(DE3)Δ58 and from 
its progenitor E. coli BL21(DE3)ΔompA were separated by 2D-electrophoresis and the protein 
maps of the two proteomes were compared using bioinformatics tools. A substantial 
reduction of protein spots was clearly visible when the 2D maps were compared (Figure 11A-
B). Interestingly, our previous characterization of progenitor OMVs by 2DE/mass 
spectrometry had led to the identification of several proteins including 42 out of the 57 
proteins encoded by the deleted genes. All the spots corresponding to these 42 proteins were 
not present in the 2D map of OMVs from E. coli BL21(DE3)Δ58 (Figure 11C). 
 
Figure 11: Silver stained 2DE gels of OMVs from E. coli BL21(DE3)ΔompA (A) and Δ58 (B) strains. (C) Zoomed areas of 
2DE gels Red circles visualize significant qualitative differences detected in E. coli BL21(DE3)ΔompA (spots encircled in 
red) and not in E. coli BL21(DE3)Δ58 (empty red circles). Four examples of proteins are shown: Maltoporin (LAMB), 
Periplasmic oligopeptide-binding protein (OPPA), FKBP-type peptidyl-prolyl cis-trans isomerase (FKBA), and ABC 




7.4 Attenuation of LPS reactogenicity in E. coli BL21(DE3)Δ58  
One of the main concern regarding OMVs as an adjuvant platform is their reactogenicity 
mediated by LPS67. LPS is composed of three main structural domains: O-specific 
polysaccharide, the core polysaccharide and Lipid A. This latter component is naturally 
present in E. coli in a hexa-acylated form and it is recognized by TLR4, a receptor that belongs 
to the PRR family. Lipid A binding to TLR4/MD2 complex results in dimerization of the 
receptor, thus leading to the activation of an intracellular signaling which ultimately results in 
the production of inflammatory cytokines. 
The Lipid A interaction to TLR4/MD2 occurs via its acyl moieties 15 and it has been shown that 
Lipid A carrying a lower number of acyl chains has a reduced TLR4 agonistic activity39. The 
production of penta-acylated Lipid A in E. coli can be achieved by inactivating two genes of 
the lipid A biosynthetic pathway (msbB and pagP), which encode two acyltransferases 
enzymes (Figure 12). 
 
Figure 12: Schematic overview of hexacylated and pentacilated LPS. Lipid A component of LPS is usually present in 
highly-reactogenic hexacylated conformation. Mutations in msbB and pagP genes should result in low-reactogenic 
pentacylated conformation.  
 
Therefore, E. coli BL21(DE3)Δ58 strain was further modified by introducing two additional 
mutations in the msbB and pagP genes by using CRISPR/Cas9 editing genome protocol. The 
new derivative was named E. coli BL21(DE3)Δ60. 
The hTLR4 agonistic activities of OMVs from E. coli BL21(DE3)ΔompA, E. coli BL21(DE3)Δ58 
and E. coli BL21(DE3)Δ60 using a hTLR4 activation assay based on HEK-Blue™ hTLR4 cells. 
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These cells, upon stimulation of their surface-exposed hTLR4 with a proper TLR4 agonist, 
activate the expression of a reporter gene encoding an alkaline phosphatase, whose activity 
is proportional to the potency of the TLR4 agonist. As shown in Figure 13, E. coli 
BL21(DE3)Δ60-derived OMVs had a hTLR4 agonistic activity almost one order of magnitude 
lower than the agonistic activity of OMVs from E. coli BL21(DE3)Δ58 and from their progenitor 
E. coli BL21(DE3)ΔompA. 
 
 
Figure 13: Human Toll Like Receptor 4 (hTLR4) activation analysis by OMVs from E. coli BL21(DE3)ΔompA, E. coli 
BL21(DE3)Δ58 and E. coli BL21(DE3)Δ60. LPS reactogenicity was tested through hTLR4 activation assay based on a 
colorimetric reaction to detect SEAP activity. OMVs were isolated from different strains and were initially diluted to a 
concentration of 10,000 ng/ml and then serial dilutions of 10-fold were prepared. OMVs from E. coli BL21(DE3)ΔompA 
(blue), E. coli BL21(DE3)Δ58 (red) and E. coli BL21(DE3)Δ60 (dark green) were compared. For each curve, dashed lines 
indicate the potencies of OMVs as agonists of hTLR4. 
 
7.5 E. coli BL21(DE3)Δ58 and Δ60 strains releasing proteome-minimized OMVs 
show a significant increase in OMV production capacity  
To be exploited as a vaccine platform, OMV production has to be scaled up to volumes 
compatible with industrial needs. Therefore, the kinetic growth and the OMVs production of 
E. coli BL21(DE3)ΔompA(pET_empty), E. coli BL21(DE3)Δ58(pET_empty) and E. coli 
BL21(DE3)Δ60(pET_empty) were tested in the bioreactor. Growth was carried out in a 2 l 
fermentation unit in LB supplemented with ampicillin (100 ug/ml, final concentration), 15 g/l 
glycerol, 0.25 g/l MgSO4. The temperature was kept at 30°C until OD600 = 0.5, and then the 
temperature was shifted down to 25°C. The growth parameters were: pH 6.8 (±0.2), dO2 > 
30% and rpm between 280-500. As shown in Figure 11, all three strains had similar growth 
kinetics. By contrast, E. coli BL21(DE3)Δ58 showed an 11.2 fold increase in OMV production 
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compared to its progenitor, while E. coli BL21(DE3)Δ60 OMV production was 7-fold higher 
than E. coli BL21(DE3)ΔompA (Figure 14).  
 
 
Figure 14: Analysis of growth kinetic and OMV productivity for E. coli BL21(DE3)ΔompA, E. coli BL21(DE3)Δ58 and E. 
coli BL21(DE3)Δ58 in the bioreactor. (A) The growth of E. coli BL21(DE3)ΔompA (red), E. coli BL21(DE3)Δ58 (red) and E. 
coli BL21(DE3)Δ60 (green) in bioreactor (2 l, 30 °C and then 25 °C, for 10h) was followed at regular intervals. (B) The bar 
graph shows the volumetric yield of total protein content in OMVs purified from E. coli BL21(DE3)ΔompA (black), E. coli 
BL21(DE3)Δ58 (red) and grown E. coli BL21(DE3)Δ60 (green) a bioreactor. 
 
7.6 Expression of heterologous antigens in the strains releasing proteome-minimized 
OMVs 
Next, the expression of heterologous antigens and their delivery to the OMV compartment 
was analyzed in E. coli BL21(DE3)Δ58 and E. coli BL21(DE3)Δ60. 
First, we investigated the surface delivery of heterologous antigens by flow cytometry. Three 
antigens were tested. Two of them were constituted by the Neisseria lipoprotein Fhbp fused 
to (i) the 13 aa peptide LEEKKGNYVVTDH belonging to EGFRvIII (EGFRvIIIpep), a mutated form 
of the human epidermal growth factor receptor (EGFR)68, and (ii) the D8-FAT1 epitope 
IQVEATDKDLGPNGHVTYSIVTDTD expressed in human colon cancer69.. The third antigen was 
D8-FAT1 fused to the S. aureus protein FhuD2.  
The plasmids encoding the fusion proteins were used to transform E. coli BL21(DE3)ΔompA 
and E. coli BL21(DE3)Δ58. The strains were grown in flask at 37°C to mid-log phase and antigen 
expression was induced for 2 hours by the addition of 0.1 mM IPTG. Cells were collected, 
incubated with the specific antibodies and subsequently with secondary Alexa Fluor®488 anti-




Interesting, E. coli BL21(DE3)Δ58 strain shows a higher capacity to express all three selected 
heterologous antigens on its surface with respect to its progenitor (Figure 15).  
 
Figure 15: Heterologous antigens are exposed on the surface of E. coli BL21(DE3)ΔompA and E. coli BL21(DE3)Δ58. 
Flow cytometry analysis. Bacterial cells from BL21(DE3)ΔompA and E. coli BL21(DE3)Δ58 were transformed with (A) pET-
Fhbp-vIII 3x (B) pET-Fhbp-D8-FAT1 3x and (C) pET-fhuD2-D8-FAT1 3x. The strains were stained with rabbit α-specific 
epitope antibodies. Signal was detected using Alexa Fluor® 488 α-rabbit IgGs antibodies. As a control, cell were stained 
with Alexa Fluor® 488 α-rabbit IgGs antibodies only (not shown). 
 
Next, the OMV compartmentalization of the following five antigens was investigated: SpA, 
LukE and FhuD2 from S. aureus, and the two fusion proteins FhuD2-D8-FAT1 3x and FhuD2-
OVA 3x.  
E. coli BL21(DE3)Δ58 and E. coli BL21(DE3)Δ60 were transformed with the antigen-encoding 
plasmids and the engineered strains were analyzed for their capacity to release OMVs carrying 
the corresponding recombinant antigen. The strains were grown in flask at 30°C to mid-log 
phase and antigen expression was induced for 4 hours by the addition of 0.1 mM IPTG. Finally, 
the cell cultures were harvested by centrifugation and OMVs were purified from the filtered 
supernatant. The expression of the heterologous antigens in the purified OMVs was analyzed 
by SDS-PAGE. All the 5 antigens were efficiently compartmentalized in the OMVs with an 




Figure 16: Efficient expression of heterologous antigens in OMVs derived from E. coli BL21(DE3)Δ58 and Δ60 strains. 
SDS-PAGE analysis of 5 μg of OMVs purified from E. coli BL21(DE3)Δ58 and Δ60 pET-Lpp-fhuD2 (fhuD2 OMVs), pET-Lpp-
LukE (LukE OMVs), pET-Lpp-SpA (SpA OMVs), pET-Lpp-FhuD2-D8-FAT1 3x (FhuD2-D8-FAT1 3x OMVs) and pET FhuD2-
OVA 3x (FhuD2-OVA 3x OMVs). Heterologous antigens are indicated with an arrow.  
 
7.7 Immunogenicity of engineered OMVs from E. coli BL21(DE3)Δ58 and E. coli 
BL21(DE3)Δ60 strains  
We next asked the question whether OMVs from engineered E. coli BL21(DE3)Δ58 and E. coli 
BL21(DE3)Δ60 could induce antigen-specific immune responses in experimental animals. To 
this aim, CD1 outbred mice were immunized i.p. three times at days 0, 14 and 28 with 5 μg of 
SpA-OMVs, LukE-OMVs, FhuD2-OMVs and D8-FAT1-OMVs derived either from E. coli 
BL21(DE3)Δ58 or E. coli BL21(DE3)Δ560. After two weeks from the third immunization, sera 
were collected and antigen-specific antibodies titers were analyzed by ELISA. To this aim, 
plates were coated with 200 ng/well of antigen (FhuD2, LukE and SpA were purified from E. 
coli while D8-FAT1 was chemically synthesized (see Materials and Methods)) and incubated 
with different dilutions of the corresponding sera. Antibody binding was finally revealed using 
goat anti-mouse IgG conjugated to alkaline phosphatase. As shown in Figure 17, all 
engineered OMVs elicited good antigen-specific antibody titers and no significant difference 




Figure 17: Antigen-specific IgG titers from mice sera elicited by immunization with OMVs from E. coli BL21(DE3)Δ58 
and Δ60 strains expressing either FhuD2, LukE, SpA or D8-FAT1. Bar graphs represent total IgG titers for sera obtained 
from mice immunized with OMVs purified from E. coli BL21(DE3)Δ58 (red) and E. coli BL21(DE3)Δ60 (green) expressing 
either FhuD2, LukE, SpA or FhuD2-D8-FAT1 3x, calculated as dilutions corresponding to an absorbance of 2. 
 
Next, we analyzed if OMVs engineered OMVs FhuD2-OVA 3x could induce epitope-specific 
CD8+ T cell response. To this aim, we immunized C57BL/6 mice with 5 μg of FhuD2-OVA 3x 
OMVs derived either from E. coli BL21(DE3)Δ58 or E. coli BL21(DE3)Δ60.  
Mice were vaccinated two times on day 0 and day 7. At day 12 spleen was collected and 
splenocytes were stimulated with 2mg/ml of OVA peptide or as a control with an irrelevant 
peptide. INFγ producing CD8+ T cells analyzed by flow cytometry and OVA-specific CD8 T cell 
population was calculated as a percentage of the whole CD8 T cells. As shown in Figure 18, 
both FhuD2-OVA OMVs from E. coli BL21(DE3)Δ58 and E. coli BL21(DE)Δ60 were shown to 
stimulate OVA-specific CD8+ T cell. Interestingly, stimulation with OMVs from E. coli 
BL21(DE3)Δ60 appeared to be particularly pronounced, the OVA-specific IFN-γ+ CD8+ T cells 






Figure 18: OMVs derived from E. coli BL21(DE3)Δ58 or Δ60(pET-Lpp-FhuD2 OVA 3x) elicit specific CD8 T cell response 
Splenocytes from mice treated with OMVs derive from E. coli BL21(DE3)Δ58(pET-Lpp-fhuD2 OVA 3x) or E. coli 
BL21(DE3)Δ60(pET-Lpp-fhuD2 OVA 3x) were in vitro stimulated with OVA peptide or with an unrelated peptide mix as 







OMVs are being extensively and successfully utilized in preclinical and clinical settings for 
prophylactic vaccination against infectious diseases. Their unique adjuvanticity, which directs 
the immune responses toward a Th1 profile, and the ease with which they can be manipulated 
and purified have attracted the attention of several academic and industrial groups. There are 
a number of bacterial OMV-based vaccines that are already available for human use. 
However, for full-blown exploitation of OMVs as a vaccine platform, a few aspects require 
optimization. They include: 1) development of universal and efficient strategies for OMV 
engineering, 2) reduction of OMV endogenous proteins to avoid potential interference in the 
elicitation of proper immune responses against heterologous antigens, and 3) the modulation 
of the potent OMV adjuvanticity to mitigate the risk of unwanted reactogenic responses. 
The aim of this work was twofold. First, to apply synthetic biology to create a novel E. coli 
derivative releasing proteome-minimized OMVs featuring high immunogenicity and low 
reactogenicity. Second, to demonstrate the usefulness of such strain as a platform for 
infectious disease and cancer vaccines. 
We believe that this study has generated a number of relevant results. 
First, thanks to the combination of in-silico analysis and 2D Electrophoresis coupled to Mass 
Spectrometry we have been able to define a detailed map of the proteins present in the OMVs 
from E. coli BL21(DE3)/∆ompA. Importantly, many of the proteins have been defined not only 
in qualitative but also in quantitative terms, and we now have good information on which are 
the most and least abundant proteins of the OMV proteome. Our study can be useful to better 
understand the biogenesis and functions of E. coli OMVs. Furthermore, such information can 
be exploited in the development of new diagnostic, drug and vaccine targets.  
A second important contribution of this work has been the development of a genome editing 
protocol based on the cutting edge CRISPR/Cas9 technology. The exploitation of CRISPR/Cas9 
protocols for prokaryotic genome editing had been published by a number of groups61,70,71. 
However, information on the broad efficiency and the robustness of the technology was 
missing. To fill this gap, we systematically tested different parameters including, the sequence 
of the gRNA, the length and concentration of the donor DNA, and use of ss-dDNA and ds-
dDNA to define the most effective conditions for gene knock out in E. coli.  
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As far as the the selection of the gDNA is concerned, any sequence next to the PAM 
trinucleotide should represent a good target site for the Cas9 cleavage. However, we found 
that 10% of the designed gDNA did not promote Cas9 DSB with high specificity. Although we 
still do not have a plausible explanation for this phenomenon (we looked for the presence of 
sequences forming internal stem-loop structures, or partially complementary to other 
chromosomal regions not carrying the NGG trinucleotides) our work provides a simple and 
effective protocol to discriminate “good” from “bad” gDNA, which simply involved a colony 
counting step after transformation with gRNA-encoding plasmid. 
 Court and co-workers demonstrated that “λ Red recombineering” in E. coli is more efficient 
in promoting mutagenesis event if performed with Lg-ss-dDNAs than Ld-ss-dDNAs. Like other 
authors62,71, we confirmed the superiority of the Lg-ss-dDNA even when “λ Red 
recombineering” is combined with CRISPR/Cas9, a situation where the mechanism that leads 
to the introduction of the site-specific mutation must be coupled to the mechanism of double-
stranded DNA repair. However, we showed that ds-DNA clearly outperforms ssDNA as donor 
DNA, and therefore our work offers an important guideline for optimal gene inactivation.  
One of the main features of our protocol is the speed with which genes can be enactivated: 
multiple mutations can be introduced at a pace of one mutation every two days. This was 
possible thanks to the strategy we used to remove the high copy number plasmid pCRISPR-
SacB-gDNA after each mutagenesis step. Different strategies have been used to remove high 
copy number plasmids, a classical one being the use of a temperature sensitive origin of 
replication70. We exploted the toxic effect of the SacB gene when E. coli is grown in media 
containing high concentrations of sucrose. This strategy, which was previously reported by 
others groups for chromosomal gene knock-in/knock-out experiments72,66, was previously 
suggested for plasmid curing by others73, and we unequivocally validated its effectiveness in 
this work.    
To allow the simultaneous inactivation of two different loci, the pCRISPR-SacB plasmid can be 
modified to carry two different gDNA sequences. We mimicked the conformation of CRISPR 
array using the configuration repeat-gDNA1-repeat-gDNA2-repeat achieving high frequency 
of mutation. Previously, Yu Jiang performed the simultaneous knockout of two different genes 
but when using synthetic ssDNA donor they were not able to recover double mutant 
colonies71. 
A third important message of this work is that, by using the CRISPR/Cas9 genome editing 
protocol developed in our laboratory, we demonstrated for the first time that a considerable 
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proportion of proteins belonging to the OMV proteome can be eliminated without impairing 
cell viability and growth rate of the mutated strains, at least under laboratory conditions. In 
particular, we managed to create a strain, we named E. coli BL21(DE3)Δ58, carrying the 
deletion of 58 genes coding for OMV proteins. 
From a scientific standpoint, this information paves the way to a better understanding of 
function and interaction of proteins belonging to the periplasmic and outer membrane 
compartments of E. coli. In our attempt to simultaneously inactivate genes encoding OMV-
associated proteins (proteins belonging to the “dispensable” family according to the Keio 
collection), we attempted the deletion of 91 dispensable genes and we found that the 
deletion of 33 of them was not compatible with the presence of the other 58 mutations. The 
information about the incompatibility of certain combinations of mutations could shed light 
on the biological role of the mutated proteins, particularly of those with unknown function. It 
is in fact conceivable to hypothesize that if certain mutations are incompatible, the 
corresponding inactivated proteins might share vital functions the cell tries to secure through 
functional redundancy. 
From a translational viewpoint, E. coli BL21(DE3)Δ58 strain has a number of interesting 
features.  
First of all, we discovered that the removal of the 58 OMV proteins led to the release of an 
impressive amount of OMVs. When grown in the bioreactor, we consistently obtained more 
than 60 mg/l of OMVs (protein content), a quantity approximately 11-fold higher than the 
yield obtained from the progenitor. The mutation of vacJ, the last gene mutation added to 
the strain, appeared to substantially contribute to the hyper-vesiculating phenotype, even 
though most of the intermediate mutant strains also showed a propensity to release high 
quantities of OMVs. VacJ is part of the VacJ/Yrb ABC phospholipid transporter whose 
inactivation has been proposed to increase vesiculation through a novel mechansim74. 
Second, the inactivation of the 58 endogenous OMV proteins does not impair the capacity of 
E. coli BL21(DE3)Δ58 strain to accumulate heterologous antigens in the vesicular 
compartment. Indeed, we tested the expression of a number of antigens and we found that 
all of them could be efficiently delivered to the OMVs, their expression ranged from 
approximately 5% to over 20% of total OMV proteins. Interestingly, when the heterologous 
proteins were expressed as lipoproteins, E. coli BL21(DE3)Δ58 was found to efficiently 
delivered such proteins to the cell surface with very high efficiency. The mechanisms which 
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make E. coli BL21(DE3)Δ58 a better strain for surface lipoprotein exposition with respect to 
its E. coli BL21(DE3)/∆ompA progenitor remain to be fully elucidated.  
Third, we showed that OMVs from E. coli BL21(DE3)/∆58 engineered with a number of 
heterologous antigens elicit excellent immune responses in experimental animal models. This 
is true for antibody responses but also for cell-mediated immunity. In particular, we showed 
that OMVs decorated with a fusion protein carrying the OVA CD8+ T cell epitope, induced 
OVA-specific CD8 T cell population, supporting the data that OMVs elicit potent cell mediated 
responses75.  
Fourth, our data showed that the potential reactogenicity of OMVs from E. coli BL21(DE3)/∆58 
could be modulated by altering the LPS biosynthetic pathway. LPS is the main OMV structure 
that affect safety, in fact LPS naturally results in excessive secretion of pro-inflammatory 
cytokines in organisms67. We created a new detoxified OMV strain by inactivating in E. coli 
BL21(DE3)/∆58 two genes involved in the acylation of Lipid A (msbB and pagP), E. coli 
BL21(DE3)/∆60, which released OMVs featuring a reduced TLR4 agonistic activity, expanding 
OMVs safety in vaccine platforms.  
Such strain maintained the same properties as E. coli BL21(DE3)/∆58 in terms of heterologous 
antigen expression in OMVs and immunogenicity, thus representing a promising candidate 
for the development of novel vaccines having both of low-toxicity and high-immunogenicity. 
In conclusion, we believe that our work represents an important step-forward for the 
optimization of OMVs as vaccine platform. Our future plans are to confirm the usefulness  of 
E. coli BL21(DE3)/∆58 and  E. coli BL21(DE3)/∆60 strains in preclinical models, with the 
ultimate goal to reach the clinics for cancer applications in a few years from now (2021-2022).    
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9 Materials and methods 
9.1 Bioinformatics  
The follow proteome analysis tools were used to identify bioinformatically the “surfactome” 
of E. coli: Proteome Analyst, SOSUI-GramN and PSORTb version 3.0.2. The “Keio collection”76, 
was used as a basis to evaluate both the biological functions and the non-essentiality of the 
selected genes listed in (Results Table 1). To properly select the gDNA and to avoid off-target 
effects of Cas9 we use the tool BLAST as previously described77.  
9.2 Construction of plasmids 
The pCasRed plasmid carries a chloramphenicol resistance gene (CmR) and encodes the Cas9 
nuclease, the λ Red (Exo, Beta, Gam) cassette and the tracrRNA. The Cas9 gene and the 
tracrRNA coding sequence are under the control of constitutive promoters while the λ Red 
gene cassette is transcribed using an arabinose-inducible promoter. The pCas9 plasmid 
(ADDGENE #42876)64 was used as template for the construction of pCasRed plasmid and the 
λ Red cassette was PCR amplified from pKOBEG plasmid65 and was cloned into pCas9 plasmid 
using the polymerase incomplete primer extension (PIPE) cloning method78 as described 
previusly77.  
The pCRISPR-SacB plasmid, derived from pCRISPR plasmid (ADDGENE #42875)64, where a 
kanamycin resistance gene (KmR) is fused to the SacB gene encoding the Bacillus subtilis 
levansucrase, carries the synthetic DNA fragment (gDNA) coding for the guide RNA necessary 
to drive the Cas9-dependent double stranded break at the desired site of the bacterial 
genome. The construction of the pCRISPR-SacB plasmid was carried out by the PIPE method 
in two steps as described priviusly77. First, the kanamycin resistance cassette of pCRISPR 
plasmid was replaced by a “cat-sac cassette” containing the chloramphenicol 
acetyltransferase gene, along with the SacB gene, from pKM154 plasmid (ADDGENE 
#13035)79.  
Plasmids expressing the gRNAs, were constructed by phosphorylation and annealing of 
oligonucleotides (gDNAs) (Zerbini et al. 2017), followed by ligation into pCRISPR (or pCRISPR-
SacB) digested with BsaI (New England BioLabs). The resulting constructs were used to 
transform E. coli DH5α strain (Invitrogen) and the plasmids prepared by QIAprep Spin 
Miniprep Kit, Qiagen (QIAGEN kit) were analyzed by DNA sequencing. 
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Plasmids expressing heterologous antigens were made by PIPE method and were previously 
cloned in our laboratory in the pET21b+ plasmid. 
The construction of pET-Nm-FHbp and pET-Nm-FHbp-vIII 3x plasmids expressing the Neisseria 
meningitidis FHbp and FHbp fused to three repeated copies of EGFRvIII peptide was cloned as 
previously described44. 
To cloning the constructs expressing the S. aureus antigens LukE, FhuD2 and SpA the coding 
sequences of the antigens were chemically synthetized (Genart-Invitrogen) and PCR amplified 
using the primers listed below. The PCR products were inserted into pET-Lpp plasmid, pET21 
derivatives carrying the sequence encoding the leader peptide for secretion of E. coli Lpp using 
the PIPE cloning method. Plasmids were linearized using the primers couples: Lpp-R-
plasmid/nohisflag. The DNA mixtures were then used to transform E. coli HK100 competent 
cells and the correctness of the cloning was verified by sequence analysis. 
Table 5: Primers for antigens fusion to the Lpp Leader sequence and cloning into pET21B 









For the construction of pET-Fhbp-D8-FAT1 3x and pET-FhuD2-D8-FAT1-3x, three copies of D8-
FAT1 were fused to the C-terminus of the S. aureus Fhbp or FhuD2 lipoprotein. D8-FAT1 
minigene was constructed by assembling six complementary oligonucleotides (listed below). 
The assembled DNA fragment was amplified with primers F-FATFH/R-FATFH F-FATFhuD2/R-
FATFhuD2 (Appendix) to make its extremities complementary to linearized pET21-Fhbp and 
pET21-FhuD2. pET21-Fhbp and pET21-fhuD2 were linearized using primers fHbp-F/fHbp-R 
and fhuD2-F/ fhuD2-R, respectively. The DNA mixtures were then used to transform E. coli 





Table 6: Oligos used to assemble the synthetic D8-FAT1 minigene  

















To clone pET-FhuD2-OVA 3x, three copies of OVA epitopes fused with a liker of glycine-glycine 
was synthetized and purchased from GeneArt® Gene Synthesis (LifeTechnologies). pET-FhuD2 
was linearized using Nohisflag and FhuD2-Rev primers, OVA minigene 
(CAGCTGGAAAGCATTATTAACTTTGAAAAACTGACCGAAGGTGGTCAGCTGGAAAGCATTATTAAC
TTTGAAAAACTGACCGAAGGTGGTCAGCTGGAAAGCATCATCAACTTCGAAAAACTGACCGAA) was 
amplified by PCR using primers couple OVAPSP-F/OVAPSP-R. Finally, PCR products were 
mixed together and used to transform E. coli HK100 competent cells. 
 
Table 8: Primers to insert OVA mini gene into pET21-FhuD2 
OVAPSP-F  TAATTAAAGCTGCAAAACAGCTGGAAAGCATTATTAACTTTGAAAAAC  
OVAPSP-R  TGGTGATGGTGATGTTATTCGGTCAGTTTTTCGAAGTTGATGATGCTTTC  
FhuD2-Rev  TTTTGCAGCTTTAATTAATTTTTCTTTTAAATCTTTACGC  
Nohisflag  TAACATCACCATCACCATCACGATTACAAAGA  
 
9.3 Bacterial strains and culture conditions  
E. coli DH5α strain was routinely grown in LB broth (SIGMA) at 37 °C and used for cloning 
experiments. E. coli BL21(DE3)∆ompA strain and its mutant derivatives strains were grown in 
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LB broth at 37 or 30 °C when required, and were employed for genome editing experiments 
and antigen expression analysis. Stock preparations of strains were prepared in LB + 20% 
glycerol and stored at −80 °C. Each bacterial manipulation was started using an overnight 
culture from a frozen/glycerol stock. When required, kanamycin and chloramphenicol or 
ampicillin were added to final concentrations of 50 μg/ml, 25 μg/ml or 100 μg/ml, 
respectively. 
For fermentation processes, an EZ control bioreactor (Applikon) was used and condition were 
set as follows: volume 2 l; temperature 30°C until OD600 0.5, then growth continued at 25°C; 
pH 6.8 (±0.2), dO2 > 30%; rpm 280-500 rpm; at OD600 1.0 feed was performed by adding 1 
ml ampicillin (100 mg/ml), 15 g/l glycerol, 0.25 g/l MgSO4.  
9.4 Competent cell preparation  
Chemically competent cells were used to prepare E. coli BL21(DE3)∆ompA/pCasRed and to 
transform pET plasmid encoding heterologous antigen in E. coli BL21(DE3)∆ompA, E. coli 
BL21(DE3)Δ58 and E. coli BL21(DE3)Δ60. Cells from glycerol stock were inoculated in 5 mL LB 
and incubated overnight (O/N) at 37°. The pre-cultures were diluted to an optical density at 
600nm (OD600nm) of 0.1 in 50 ml LB and incubated at 37°C until an OD600nm of 0.4-0.6 was 
reached. The cell cultures were harvested through centrifugation at 4 °C, 2.500 x g for 20 
minutes, resuspended in 5 ml of ice-cold, sterile 100 mM MgCl2 and kept in ice for 30 minutes. 
Subsequently, cells were centrifuged at 4 °C, 2.500 x g for 20 minutes, resuspended in 1 mL of 
ice-cold, sterile 100 mM CaCl2 in 15% glycerol and aliquoted for storage at -80°C. 100 ng of 
purified pCasRed plasmid or pET plasmid containing the gene of interest were mixed with 50 
μl of chemically competent cells and kept in ice for 30 minutes. Subsequently, cells were 
transferred to a thermoblock and heat-shocked at 42°C for 45 seconds and placed on ice for 
another 2 minutes. 950 μl of LB was added to the reaction and incubated for 1h at 37°. For 
the selection step, cells were plated on LB-agar plates, containing 25 μg/ml chloramphenicol 
or 100 μg/ml, and incubated overnight at 37°C. 
Mutagenesis experiments were performed using electro competent cell. E. coli 
BL21(DE3)∆ompA and its mutant derivative strains carrying pCasRed plasmid were used. To 
prepare electro competent cells a 5 ml overnight culture (LB medium) inoculated from a single 
colony of E. coli BL21(DE3)∆ompA(pCasRed) or its mutant derivative strains obtained from an 
LB-agar plate was grown LB medium with 25 μg/ml chloramphenicol at 37 °C under vigorous 
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shaking. The overnight culture was diluted to an OD600 of 0.1 and grown at 37 °C under 
shaking (200 r.p.m.) to an OD600nm of 0.2 and then l-arabinose was added to a final 
concentration of 0.2% for λ Red induction. After induction, the culture was grown to an OD600 
of 0.7 and then cells were washed, aliquoted and store at -80°C.  
9.5 Gene knockout using CRISPR-Cas9 
For mutagenesis experiments oligonucleotides (donor DNA or dDNAs) (see Zerbini et al. 2017) 
were HPLC purified grade. The dDNAs were designed to delete a region ranging from 30 (∆30) 
to 2325 (∆2325) nucleotides from target genes, removing the protospacer and PAM regions 
adding an in-frame stop codon downstream the deleted region. For the leading and lagging 
strand design, the oligonucleotides annealing to the 3′ > 5′ strand moving clockwise from OriC 
up to ter were Ls-ss-dDNAs, while oligonucleotides annealing to the same strand but moving 
counterclockwise from OriC up to ter were Lg-ss-dDNAs. The opposite was true for the 
oligonucleotides annealing to the 5′ > 3′ strand moving clockwise from OriC up to ter and for 
those annealing to the same strand moving counterclockwise from OriC to ter. The ds-dDNAs 
were generated by annealing 10 µg of both forward and reverse oligonucleotides in a total 
volume of 20 µl at 95 °C for 5 min and allowing the reaction mixture to cool down at room 
temperature. The annealing reaction was verified by loading 500 ng of each single stranded 
oligonucleotides and 1 μg of total DNA in the annealing reaction and by visualizing the bands 
using ATLAS ClearSight DNA Stain (BIOATLAS). For CRISPR/Cas9-mediated gene knockouts 50 
μl of competent cells were electroporated using 1 mm Gene Pulser cuvette (Bio-Rad) at 1.8 
kV with 100 ng of pCRISPR-gDNA or pCRISPR-SacB-gDNA plasmid and either 1 or 10 ug of 
oligonucleotide donor DNA. As control, 100 ng of an empty pCRISPR plasmid was used. Cells 
were then immediately re-suspended in 1 ml of LB medium and allowed to recover at 30 °C 
for 3 h under agitation before being plated on LB agar with 25 μg/ml chloramphenicol and 50 
μg/ml kanamycin and incubated at 37 °C overnight. Mutants were screened by colony PCR 
using GoTaq master mix (Promega-M7123). Individual colony were picked and directly 
resuspended in PCR reaction mix and DNA amplification was carried out according to the 
standard cycling GoTaq protocol. 
9.6 OMV purification and SDS-PAGE  
E. coli BL21(DE3)ΔompA strain and its mutant derivative strains were transformed with pET 
empty plasmid or encoding the genes of interest. Recombinant clones were grown at 30°C 
and 180 rpm in LB medium (starting OD600 = 0.05) and, when the cultures reached an OD600 
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value of 0.5, protein expression was induced by addition of 0.1 mM IPTG (Sigma-Aldrich). After 
4 hours, culture supernatants were separated from living bacterial cells by a centrifugation 
step at 6,000 x g for 15 minutes followed by a filtration through a 0.22 μm pore size filter 
(Millipore) or for larger volume Tangential Flow Filtration was performed using a Hollow Fiber 
cartridge UFB-500-C-3MA (General Electrics). Supernatants were then subjected to high-
speed centrifugation (200,000 x g for 2 hours) and pellets containing the OMVs were finally 
re-suspended in sterile 1X PBS. OMVs amounts were estimated by measuring protein 
concentration using DC protein assay (Bio-Rad). 10 μg of OMVs (protein content) were 
resuspended in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Laemmli buffer and heated at 100°C for 10’. Proteins were separated using Any kD™ 
Criterion™ TGX Stain-Free™ Protein Gel (BioRad) in TrisGlicyne buffer (BioRad). Finally 
proteins were revealed by Coomassie Blue staining. 
9.7 Purification of recombinant S. aureus antigens  
Recombinant S. aureus antigens were purified using the TEV protease purification strategy80. 
Briefly, the synthetic genes coding for SpA, LukE and FhuD2 were fused at their 5’ to the 
sequence coding for a His 6 -tag and the TEV cleavage site. The constructs were cloned in a 
pET15 plasmid downstream of a T7 inducible promoter and expressed in E. coli BL21(DE3) 
strain. Bacterial biomass (5 g wet weight was resuspended in 50 ml buffer A (50 mM NaH2PO4, 
300 mM NaCl, pH 8.0) in the presence of a protease inhibitor (0.2 mM PMSF), sonicated 
thoroughly at 4°C and the total cell lysate was finally centrifuged (15.000 x g, 30 min, 4°C). 
The supernatant was filtered (0.22 µm) and applied to Ni-affinity chromatography (IMAC) 
using an ÄKTA purifier System (GE) and a 5 ml HiTrap IMAC column (GE) monitoring 
absorbance at 280 nm. Protein binding and column washing was performed at concentrations 
of 20 mM and 50 mM imidazole, respectively. Bound proteins were elute using a linear 
gradient by increasing buffer B (50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole, pH 8.0) 
from 10% to 100% over 6 CV. Pooled fractions containing the His-tagged recombinant protein 
was dialysed against buffer A at 4°C and subsequentlydigested with TEV protease (1 mg per 
100 mg protein) in the presence of 5 mM β-mercaptoethanol. TEV-digested protein pool was 
applied to Ni-affinity chromatography and the flow-through, containing the untagged 
recombinant protein, was applied to a final polishing step by size-exclusion chromatography 




9.8 In vitro assay for human Toll Like Receptor 4 activity analysis 
The experiment was conducted to detect the level of activation of the human Toll Like 
Receptor 4 (hTLR4) using HEK-Blue™ hTLR4 Cells and QUANTI-Blue (InvivoGen) as substrate 
according to the manufacturer’s protocol. 
OMVs isolated from E. coli BL21(DE3)ΔompA, E. coli BL21(DE3)Δ58 and E. coli BL21(DE3)Δ60, 
transformed with pET plasmid, were tested for hTLR4 activation and as positive control LPS 
was used. OMVs and LPS were initially diluted to a concentration of 10,000 ng/ml and then 
serial dilutions of 10-fold were performed. 20 μl of each dilution were added in the dedicated 
well on a 96-well plate and, subsequently, 180 μl of HEK-Blue™ hTLR4 Cells (~140,000 cells/ml) 
were added to each well and incubated overnight at 37°C. The following day, 20 μl of 
supernatant from SEAP-expressing HEK-Blue™ hTLR4 Cells were added to 180 μl QUANTI-
Blue™ in a new 96-well plate and incubated at 37°C for 30 min. The absorbance of the 
colorimetric reaction was measured at 655 nm using an Infinite M200PRO plate reader 
(TECAN). 
9.9 Flow cytometry on bacteria  
E. coli BL21(DE3)ΔompA or E. coli BL21(DE3)Δ58 strain transformed with either pET-Fhpb-vIII 
3x, pET-Fhpb-hFAT1 or pET-FhuD2-hFAT1 3x and were grown at 37°C and 180 rpm in LB 
medium (starting OD600 = 0.05) and, when the cultures reached an OD600 value of 0.5, 
protein expression was induced by addition of 0.1 mM IPTG (Sigma-Aldrich). After induction, 
a volume corresponding to OD=1 was collected from each culture and centrifuge at 14,000 
rpm 10’. Pellet was resuspended in 1ml PBS/BSA 1% and further diluted 1:50 in PBS/BSA 1%. 
50 μl/well were put in 96 well plate. 50 μl of 2x solution of rabbit α-vIII or α-hFAT1 antibodies 
respectively (final concentration is 8 μg/ml) in PBS/BSA 1%were added in selected wells and 
cell incubated for 1h at 4°C. Cells were then washed 2 times with 100-200 μl/well of PBS/BSA 
1% and centrifuged centrifuge for 10’ at 3500 rpm and 4°C. 100 μl/well of Alexa Fluor®488 α-
rabbit IgGs (Thermo Fisher Scientific) diluted 1:200 (final concentration is 10 μg/ml) in 
PBS/BSA1% were added in selected wells and incubated for 1h at 4°C in the dark. Cells were 
then washed 2 times with 100-200 μl/well of PBS/BSA 1% and centrifuged centrifuge for 10’ 
at 3,500 rpm and 4°C. Cells were fixed with 100 μl PBS/Formaldehyde 2% for 15’ at room 
temperature. Cells were then washed 2 times with 100-200 μl/well of PBS and centrifuged 
centrifuge for 10’ at 3,500 rpm and 4°C. Cells were finally resuspended cells in 200 μl of PBS 
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and stored at 4 °C in the dark or acquired to the Flow cytometry. Data were analyzed using 
FlowJo v10.1. 
9.10 Animal studies 
Mice were monitored twice per day to evaluate early signs of pain and distress, such as 
respiration rate, posture, and loss of weight (more than 20%) according to humane endpoints. 
Animals showing such conditions were anesthetized and subsequently sacrificed in 
accordance with experimental protocols, which were reviewed and approved by the Animal 
Ethical Committee of The University of Trento and the Italian Ministry of Health. 
For antibody titer analysis, CD1 mice were immunized intraperitoneally (i.p.) on days 0, 14 
and 28 with 5 μg of OMVs from E. coli BL21(DE3)Δ58 or Δ60 strain transformed with pET-lpp-
fhuD2, pET-lpp-Luke, pET-lpp-SpA, pET-lpp-FhuD2 hFAt1 3x plasmid. Mice blood was collected 
through cardiac puncture at day 35 and serum was obtained from blood through 
centrifugation at 2,000 rpm for 10 minutes. Pools were obtained by mixing equal volumes of 
sera from mice immunized with the same type of OMVs and then they were used to perform 
ELISA experiments.  
For T cell generation, BALB/c mice were i.p. injected on days 0 and7 with 10 μg of OVA 
engineered OMVs derived from E. coli BL21(DE3)Δ58 or Δ60 strain. On day 12 spleens were 
collected and used for to perform intracellular cytokine staining analyzed. 
9.11 ELISA 
ELISA was performed using ninety-six well plates coated with 200 ng/well of FhuD2, LukE, SpA 
recombinant protein or using Nunc Immobilizer Amino plates (Thermo Fisher Scientific) plates 
coated with 200 ng/well of D8-FAT peptide, IQVEATDKDLGPNGHVTYSIVTDTD (Genescript). 
The day after, plates were washed 3 times with PBST (0.05% Tween 20 dissolved in PBS), 
saturated with 100 ul/plate of 1% BSA dissolved in PBS for 1 hour at 37°C and washed again 3 
times with PBST. An equal amount of serum was added to the wells. Serum samples were 
initially diluted 1:300 in 1% BSA in PBS and then serial dilutions of 3-fold were performed. 
Serum samples were incubated for 1 hour at 37°C. Wells were subsequently washed 3 times 
with PBST and incubated for 1 hour at 37°C with alkaline phosphatase-conjugated goat α-
mouse total IgG (Sigma-Aldrich) at a final dilution of 1:2,000. After triple PBST wash, 100μl of 
Alkaline Phosphatase substrate (Sigma-Aldrich) were added to each well and plates were 
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maintained at RT in the dark for 30’. Finally, absorbance was read at 405nm using Tecan 
Infinite M200Pro Plate reader. 
9.12 Intracellular cytokine staining on splenocytes 
Spleens were homogenized and splenocytes filtered using a 70 μm cell Strainer (BD). After 
centrifugation at 400 x g for 7’, splenocytes were resuspended in RPMI+10%FBS and PSG and 
aliquoted in a 96-well plate at a concentration of 1x106 cells per well. Cells were stimulated 
with 2 mg/ml of OVA peptide. As positive and negative controls, cells were stimulated with 
phorbol 12-myristate 13-acetate (PMA, 0.5 mg/ml) and Ionomycin (1 mg/ml) or with 2 mg/ml 
of an unrelated peptide, respectively. After 2 hours of stimulation at 37°C, Brefeldin A (BD) 
was added to each well and cells incubated for 4 hours at 37°C. After two washes with PBS, 
LIVE/DEAD™ Fixable Near-IR Dead Cell Stain Kit (Thermo Fisher Scientific) was incubated with 
the splenocytes for 20’ at RT in the dark. After two washes with PBS and permeabilization and 
fixing with Cytofix/Cytoperm (BD) following manufacturer’s protocol, Fc receptors were 
blocked with 3 μl of α-CD16/CD32 for 15’ at room temperature. Splenocytes were stained 
with the following fluorescent-labeled antibodies: α-CD3-APC (BioLegend), α- CD4-BV510 
(BioLegend), α-CD8-PECF594 (BD), and α-IFN-γ-BV785 (BioLegend). Samples were acquired on 
a BD FACSCanto II flow cytometer. Briefly, after gating lymphocytes from all events on the 
basis of SSC-A and FSC-A, single cells were selected on SSC-A and SSC-W, excluding both 
duplets and aggregates, which would have bound more and in a nonspecific manner, 
respectively, the antibodies. Live cells were selected as negative to LIVE/DEAD™ Fixable Near-
IR Dead Cell Stain Kit (Thermo Fisher Scientific) and T lymphocytes were selected for CD3 
expression. CD4 and CD8 lymphocytes were identified as positive for CD4 and CD8 molecules, 
respectively. IFN-γ positive T cells were finally visualized against CD4 or CD8 expression 
(depending on the epitope nature), gating on the CD3 positive population. The IFN-γ releasing 
CD4 and CD8 T cell populations were calculated as percentage of IFN-γ/CD4 and IFN-γ/CD8 
double positive cells on the total of CD4 or CD8 cells, respectively. Graphs were performed 
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